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ABSTRACT 
 The most common causes of childhood interstitial lung disease (chILD) are 
autosomal recessive mutations in the gene encoding ATP Binding Cassette A3 (ABCA3) 
protein, a lamellar body (LB) associated lipid transporter exclusively expressed within 
the alveolar epithelial type II cells (AEC2s) in the lung. Instability of primary AEC2s in 
culture has prevented studies of ABCA3 mutations, resulting in limited understanding of 
disease pathogenesis. To overcome this challenge, we developed AEC2-like cells from 
human pluripotent stem cells (PSCs) in vitro, allowing study of normal ABCA3 function 
and perturbations that result from ABCA3 mutations. 
 To develop an AEC2 model that would recapitulate ABCA3 biology, we targeted 
human PSC lines with a knock-in GFP fusion reporter (ABCA3:GFP). Differentiations of 
PSCs into AEC2s (iAEC2s) resulted in exclusive expression of ABCA3:GFP in iAEC2s 
and intracellular localization to LAMP3+ vesicles, reminiscent of endogenous ABCA3. 
	
	 xi 
Moreover, we find these ABCA3:GFP+ iAEC2s express LBs, process surfactant proteins, 
and secret surfactant lipids, indicative of preserved ABCA3 function.  
 To study the effects of ABCA3 mutations using our model, we generated two sets 
of PSC reporter lines: 1) two patient-derived iPSC lines carrying rare homozygous 
E690K and W308R ABCA3 mutations predicted to affect ABCA3 function or 
trafficking, respectively, and their two syngeneic gene-corrected lines each targeted with 
the AEC2-specific knock-in fluorescent reporter SFTPCtdTomato; and 2) three syngeneic 
ABCA3:GFP knock-in iPSC lines encoding wildtype, E690K, or W308R proteins.  
 Directed differentiation of patient iPSCs into iAEC2s revealed attenuated 
secretion of surfactant-specific lipids, recapitulating clinical findings of surfactant 
deficiency. Examination of ABCA3 protein trafficking using the ABCA3:GFP fusion 
reporter revealed retained E690K and W308R mutant ABCA3 protein processing and 
trafficking compared to the wildtype protein by confocal microscopy and western blot 
analyses, however mutant iAEC2s exhibited smaller LBs, indicative of defective 
ABCA3-dependent lipid transport. Bulk RNA sequencing of mutant and gene-corrected 
SFTPCtdTomato- or ABCA3:GFP-expressing iAEC2s revealed enrichment of the TNFa-
NFkB pathway in both W308R and E690K mutant iAEC2s, validated by lentiviral 
reporter assays and secretion of NFkB-driven cytokines. Thus, we provide insights into 
how ABCA3 mutations alter AEC2 physiology and developed a platform to study other 
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Overview: childhood interstitial lung disease 
 Childhood interstitial lung disease (chILD) is a group of complex genetic diseases 
with diverse and often unknown etiologies that affects the lungs of infants and children, 
resulting in high morbidity and mortality 1-3. Typical features of chILD are breathlessness 
and hypoxemia in the presence of diffuse lung infiltrates. A diversity of presenting 
clinical phenotypes has been described, including acute neonatal respiratory distress 
syndrome, chronic interstitial fibrosis, and fatal secondary infections. Recently, these 
associated symptoms have collectively been referred to as "chILD syndrome" by the 
American Thoracic Society Committee on chILD and the chILD Research Network in 
order to provide a set of criteria to aid the diagnosis of chILD 4. Prior to these diagnostic 
guidelines, different studies have estimated the prevalence of chILD to be between 0.13-
16.2 cases/100,000 children/year 5-7 but the overall incidence of chILD is unclear as 
infants who succumb early to the disease may not be included in these estimates. With 
adoption of improved diagnostic guidelines and increased physician training, a more 
accurate estimate will likely be available in the future.  
Treatment for chILD 
 Currently, patients diagnosed with chILD are treated empirically with a variety of 
therapies including supplemental oxygen, nutritional support, immunomodulatory agents, 
artificial surfactant, as well as prophylactic vaccines and antibiotics for secondary viral 
and bacterial infections 4. To date, there have been no controlled trials of effective 




on indirect evidence, case reports, and clinical observations 8. Consequently, for infants 
with severe chILD disease, pediatric lung transplantation is often the only option for 
survival with high mortality rates post-transplant 1,3,4. The lack of effective therapies 
beyond lung transplantation for chILD highlight our limited understanding of the 
pathophysiology of chILD, necessitating further research targeted at dissecting disease 
mechanisms and how it perturbs normal lung physiology to guide the design and 
development of effective future therapies.  
Genetic causes of chILD 
 Early onset of lung disease in infancy combined with familial inheritance patterns 
have indicated a genetic component to the pathogenesis of chILD 2. Recently, significant 
advances have been made in identifying some of these causal genetic loci, allowing for 
specific non-invasive diagnostic testing, family counseling, prediction of natural history, 
and classification based on implicated disease mechanisms. These disease-causing 
mutations have been predominantly found in genes encoding proteins important in the 
synthesis, metabolism, function and catabolism of pulmonary surfactant including 
SFTPB 9,10, SFTPC 11,12, ABCA313-15, NKX2-116-18, GM-CSF receptor19,20, among which 
mutations in the ABCA3 gene is the most common21, as well as genes related to lung 
capillary development such as FOXF122,23. Even while the list of causal gene mutations 
increases, the majority of these newly discovered single-gene mutations are related to 
pulmonary surfactant metabolism, highlighting the importance of surfactant regulation 
and potentially shared mechanism of chILD pathogenesis. Elucidating the mechanisms of 




adult-onset ILD since mutations in some of the same genes that cause chILD are also 
detected in adults with ILD 24,25. 
Pulmonary surfactant: source, composition and function 
 Type II alveolar epithelial cells (AEC2) are responsible for the production of 
pulmonary surfactant26. Beyond surfactant production, AEC2s have also been known to 
play a critical role as the facultative progenitor of the distal lung to maintain cellular 
homeostasis in healthy and injured lungs through self-renewal as well as by 
differentiating into type I alveolar epithelial cells (AEC1) 27. Together, the AEC2 and 
AEC1s line the gas-exchanging chambers of the distal lung called the alveolus. 
 Pulmonary surfactant is essential in the normal respiratory cycle by reducing the 
surface tension of alveolar lumens. Surfactant is composed of a mixture of majority lipids 
(90%) and proteins (10%). The lipid component is mostly made up of 
phosphatidylcholine (PC; 70-80%), phosphatidylglycerol (PG; 10%), cholesterol (10%), 
along with minor amounts of phosphatidylinositol (PI), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), and sphingomyelin (SM) 28-30. Accounting for approximately 
half of the majority PC fraction, pulmonary surfactant is enriched in dipalmitoyl-PC 
(DPPC), which is the major surface-active component of pulmonary surfactant 30. The 
protein components of surfactant are predominantly made up of SP-A, SP-B, SP-C, and 
SP-D proteins 21. SP-B and SP-C play a role in lipid packaging and enhance the surface 
tension-lowering activity of the lipids 31. SP-A is required for the structural formation of 




SP-D is thought to be important in the regulation of alveolar surfactant pool size and 
reuptake in addition to its role in suppression of pulmonary inflammation 32,34.   
 Within AEC2s, components of surfactant are thought be synthesized in the 
cytosol, ER, and Golgi. In the fetal lung, surfactant is also synthesized within 
intracellular glycogen-laden vesicles 35. These components are then assembled in the 
precursor Golgi and lysosome-derived organelles and stored in its final form in large, 
lipid-rich, intracellular organelles called lamellar bodies (LB). Surfactant stored in 
lamellar bodies are secreted via regulated exocytosis apically by AEC2s into the alveolar 
lumen in response to catecholamines, purinoceptor agonists, and cell stretch (Fig 1.1)26. 
Once secreted into the alveolar lumen, LB and its transformed, lattice-like form called 
tubular myelin (TM) are thought to adsorb with air-water interface to form a lipid film, 
Fig 1.1 EM image of secreted lamellar bodies. Secreted lamellar bodies and newly formed tubular myelin trapped 
within the large lumen of a 21 day old rat fetal lung. Glycogen deposits (G) Membrane continuities between 




lowering surface tension to promote alveolar stability 36,37. Subsequently, sequential 
respiratory cycles release inactivated surfactant which is then retrieved by AEC2 and 
alveolar macrophages to be recycled, repackaged, or eliminated 26,37. 
Surfactant dysfunction disorders leading to chILD 
 Mutations in SFTPB, SFTPC, ABCA3, and NKX2-1 genes, all of which are 
expressed in AEC2s, have resulted in lung disease with similar clinical, radiographic, and 
histological features reviewed in 2,21. Etiology and pathogenesis of how these mutations lead 
to chILD syndrome has been studied for a limited number of high frequency or penetrant 
alleles but the pathogenesis of most causal mutations remain unknown. With the goal of 
implementing effective future therapies, research priorities outlined by the American 
Thoracic Society Committee on chILD 8 include discovery of mechanisms of chILD 
pathogenesis starting from understanding of normal lung development, growth and their 
alteration in the context of chILD; determining genetic, epigenetic, cellular and molecular 
basis of chILD diagnosis, incorporating animal and tissue culture models, as well as 
screening for clinical biomarkers using systems biology ("-omics") approaches. In an 
attempt to meet some of these goals, my dissertation research will add to our current 
understanding of chILD pathogenesis by uncovering the role of ABCA3 in normal 
AEC2 cells as well as during disease caused by ABCA3 mutations using human 
induced pluripotent stem cell-derived AEC2s. 
NKX2-1 mutations 
 NKX2-1, also known as thyroid transcription factor 1 (TTF1), is a member of the 




of the central nervous system, thyroid and the lung 38,39. Beyond its well described role as 
a marker of lung epithelial identity during development, NKX2-1 is also responsible for 
the expression of multiple genes encoding key proteins related to surfactant production in 
AEC2s including SP-B, SP-C, and ABCA3 40. Recently, deletions of one copy of the 
NKX2-1 allele were discovered in full- or near-term neonates with respiratory distress 
syndrome, choreoathetoid movements, and hypothyroidism 41,42. Subsequently, loss-of-
function mutation due to the observed loss of one allele (haploinsufficiency) was 
recognized to be linked to these symptoms in the brain, thyroid and the lung which have 
been collectively termed the "brain-thyroid-lung" syndrome 43. Pulmonary presentations 
due to NKX2-1 haploinsufficiency can be variable, ranging from neonatal pulmonary 
distress to chronic respiratory symptoms in childhood (as reviewed in Nogee, 2010). It is 
suspected that lung disease due to NKX2-1 haploinsufficiency is at least partly related to 
the decreased production of SP-B, SP-C, ABCA3 but the exact mechanism of lung 
disease is largely unknown. 
 Recently, other missense mutations at the NKX2-1 locus have been linked to 
hyperplastic pulmonary neuroendocrine cells, termed neuroendocrine cell hyperplasia of 
infancy (NEHI), with no associated neurological or thyroid symptoms 44. These findings 
highlight potential NKX2-1 mutant-specific pathogenesis of disease and symptoms as 






 Hereditary SP-B deficiency is a rare autosomal recessive disorder with a carrier 
rate of less than 1 in 20000 45, usually presenting in full-term infants with respiratory 
distress and surfactant deficiency. Patients typically exhibit signs of cyanosis and 
respiratory failure within hours of birth and these are refractory to treatment with 
surfactant replacement, ventilation, and other supportive care. The typical progressive 
respiratory failure is fatal within weeks to months of age despite assisted ventilation or 
extracorporeal membrane oxygenation (ECMO). 
 SP-B is an extremely hydrophobic protein encoded by the gene locus SFTPB on 
chromosome 2, producing a 381-amino acid pro-protein which is trafficked from the ER 
to multivesicular and lamellar bodies 31 where it is cleaved to generate a mature 79-amino 
acid 8 kDa peptide that interacts closely with PC species at the surfactant air-water 
interface. Lung disease caused by the inability to produce SP-B was the first recognized 
cause of surfactant dysfunction 46. Greater than 60% of SFTPB mutations are a 2-base 
insertion at codon 121 termed 121ins2, resulting in a frameshift mutation47. The 121ins2 
mutation causes synthesis of unstable mRNA and loss of both proSP-B and mature SP-B 
protein production. Other SFTPB mutations are thought to result in incomplete 
processing of pro-SP-B, hence active forms of SP-B peptide are absent in the alveoli 48.  
 Histologically, patients with hereditary SP-B deficiency typically have 
accumulation of eosinophilic materials in the alveolar space, lack of TM, hyperplastic 
alveolar epithelium predominantly of cuboidal AEC2s, thickening of alveolar septa 
caused by proliferation of interstitial fibroblasts and the AEC2s containing abnormally 




fusion. Targeted knock-out of the orthologous SFTPB gene mice revealed similar 
physiology including disruption in surfactant homeostasis, resulting in respiratory failure 
in newborn mice 49, suggesting that the pathogenesis of lung dysfunction is likely due to 
the lack of SP-B in AEC2 and in the alveolus. 
SFTPC mutations 
 SP-C is also a highly hydrophobic peptide secreted by AEC2s. Prior to secretion, 
SP-C is processed through enzymatic cleavage from its precursor proSP-C. Similar to SP-
B deficiency disorder, histological features of lung disease caused by SFTPC mutations 
include interstitial thickening, hyperplastic AEC2s, and evidence of alveolar damage. 
However, unlike SFTPB mutations, patients with mutations in the SFTPC gene encoding 
for SP-C can have varied age-of-onset and symptom severity ranging from neonatal 
respiratory distress syndrome to idiopathic pulmonary fibrosis in children and adults.  
 SFTPC is located on chromosome 8. So far, approximately 40 missense, splice, or 
frameshift SFTPC mutations have been found 21 with autosomal dominant inheritance 
and incomplete penetrance. The mutations are classified into two major classes of 
mutations resulting in two aberrant cellular responses. The brichos domain mutations 
located in exon 4 of the SFTPC gene have been shown to cause aberrant processing of the 
precursor proSP-C resulting in misfolding, heightened ER stress and unfolded protein 
response (UPR) leading to AEC2 apoptosis 50,51. Of all non-brichos mutations, the I73T 
mutation is the most common, represented in over 25% of SFTPC associated diseases 52. 
In contrast to brichos mutations, I73T mutant form of SP-C does not induce substantial 




normal cell autophagy and mitochondrial dysfunction, resulting in cell apoptosis 53. In 
contrast to SP-B deficiency, loss of SP-C expression by genetic mouse knock out model 
did not exhibit disease phenotypes or affect lung function 54, indicating the gain-of-toxic-
function nature of some disease-causing SFTPC mutations.  
ABCA3 mutations cause chILD syndrome 
 Of all the surfactant-related genes identified to cause chILD syndrome, autosomal 
recessive mutations in ABCA3 are the most common (as reviewed in Nogee, 2010; 
Whitsett, 2010). The first reported cases directly linking ABCA3 gene mutations to severe 
respiratory disease and symptoms of surfactant deficiency were published in Shulenin et 
al (2004). In the study, blood samples from over 300 full-term to near full-term infants 
from diverse racial and geographic backgrounds with severe respiratory disease were 
collected to identify inherited abnormalities of surfactant metabolism. For the majority of 
these infants, respiratory distress occurred within hours after birth, and radiographic 
findings were consistent with surfactant deficiency. After excluding causes of surfactant 
deficiency attributed to SFTPB or SFTPC mutations, the study identified 21 infants from 
14 families likely to have genetic basis for their lung disease. Amongst the 21 infants 
were 6 pairs of siblings and the majority of these patients died within a month after birth 
13. DNA sequencing of all 21 patients' exon and its flanking slice sites at the ABCA3 
locus revealed 5 of the 6 pairs of siblings to be concordant with ABCA3 haplotypes and 
deleterious mutations were identified in 16 of the 21 patients including frameshift 
mutations, nonsense mutations, missense mutations, and splice-site mutations. Since the 




encoding ABCA3 with varied genotype to phenotype correlation and clinical outcomes 
55,56, indicative of diverse underlying genetic mechanisms unique to potentially different 
subtypes of ABCA3 mutations.  
The role of ABCA3 in normal lung homeostasis  
  ABCA3 is a member of the ATP-binding cassette (ABC) transporter superfamily 
that transports a variety of substrates across membranes including ions (e.g. Cl-  by 
ABCC7, also known as cystic fibrosis transmembrane conductance regulator [CFTR]), 
amino acids, peptides, carbohydrates, and lipids 57. Among the different subclasses of 
ABC transporters, the ABCA subclass has been known to transport intracellular 
cholesterol and phospholipids. To date, twelve members of the ABCA subclass have been 
identified named ABCA1-12 as well as two pseudogenes (ABCA11P and ABCA17P) (as 
reviewed in Beers and Mulugeta, 2017). Specific mutations in the ABCA1 and ABCA4 
gene have been shown to cause Tangier disease resulting in high density lipoprotein 
deficiency 58 and Strgardt's macular dystrophy 59, respectively. In addition, the expression 
patterns and functions of ABCA1, ABCA3, ABCA4, ABCA6, ABCA7, ABCA9, 
ABCA10 and ABCA12 suggest distinct roles for these transporters in lipid homeostasis 
function in various subcellular compartments across many tissue types (as reviewed in 
Beers and Mulugeta, 2017). 
  The gene encoding ABCA3 is located in chromosome 16p13.3 containing 30 
exons and encoding a 1704 amino acid (180kDa) protein 60. While no protein 
crystallography data exist, a structure prediction algorithm suggests ABCA3 has four 




domain and a cytosolic nucleotide-binding domain (NBD, also known as ATP- binding 
cassette) that includes two conserved peptide motifs known as Walker A, Walker B, 
present in other proteins that utilize ATP for catalytic energy, and a Walker C signature 
motif unique to ABCA transporters 61. Comparison between human, rat, and mouse 
mRNA transcripts of ABCA3 revealed highly conserved domains both of the known 
ABC transporter domains as well as domains unique to ABCA3, supporting the 
likelihood of high homology of ABCA3 between species 62. Additional functional 
comparison with other better characterized ABC transporters suggests that the two halves 
of ABCA3 domains are predicted to form a conduit within a phospholipid bilayer that 
allows translocation of lipid substrates coupled with chemical energy harvested from the 
hydrolysis of ATP in the two NBDs.  
 While ABCA3 is expressed in other organs including liver, stomach, kidney, 
adrenal, pancreas, and the brain, ABCA3 is most highly expressed in the lung and 
specifically in the AEC2 within the lung 62,63. Within the AEC2, ABCA3 is localized to 
the outermost membrane (also known as "limiting membrane") of LBs, optimally 
positioned to promote lipid transport in this lipid laden organelle storing pulmonary 
surfactant. Prior to its localization on the limiting membrane of LBs, ABCA3 primary 
translational product is trafficked from its site of translation in the ER to the Golgi where 
it is glycosylated and then is routed to post-golgi lysosome-derived sorting vesicles (SV), 
subsequently trafficked to multivesicular bodies (MVB) and composite body (CB) 
network to lamellar body (Fig 1.2, as reviewed in Beers and Mulugeta 2017). Although 




unknown, sometime during the post-golgi ABCA3 trafficking, the protein undergoes a 
proteolysis at the N-terminus region in LAMP3+ lysosome-derived vesicles, generating a 
30-40kDa cleavage byproduct and a shortened 150kDa final translational product 64. 
 
 Although the complete list of substrates of ABCA3 is still unknown, 
bronchoalveolar lavage fluid (BAL) samples analyzed from patients born with ABCA3 
mutations have decreased levels of PC species, particularly the DSPC/DPPC 29. Since the 
majority of surfactant PC species are synthesized in the ER of AEC2s and then 
transferred via the Golgi system to the lamellar bodies, there is strong evidence that 
ABCA3 mutations resulted in inadequate transport of PC within the cellular 
compartments in AEC2. Together, the localization of ABCA3 to the LB limiting 
membrane, known roles of other ABCA transporters, and low proportion of PC in 
Fig 1.2 Intracellular trafficking of ABCA3 protein. Left, predicted topological structure of the ABCA3 
transporter, 12 containing membrane spanning helices and two nucleotide binding cassettes. Right, ABCA3 is 
synthesized and trafficked together with phospholipids and surfactant proteins routing first through post-Golgi 
sorting vesicles (SV), and subsequently trafficked via the multivesicular body (MVB) and composite body (CB) 




pulmonary surfactant from patients with ABCA3 mutations support the notion that 
ABCA3 is the major PC transporter within AEC2s 29. 
 Recent studies have found ABCA3 to play a critical role in the maturation of 
human, rat and mouse lung as well as the biogenesis of lamellar bodies within AEC2s 
62,63. ABCA3 mRNA is strongly upregulated during human and rat lung development at 
the same time as induction of messages for surfactant-associated proteins, reaching its 
highest level just before birth in rat 62. At the protein level, ABCA3 is absent between 
weeks 14 to 23 of human gestation corresponding with the pseudoglandular and 
canalicular stages of lung development 63 . Later on, ABCA3 staining is detected in the 
lung epithelium during 26 to 27 weeks of gestation with intracellular staining patterns 
surrounding small cytoplasmic organelles 63. This is consistent with the temporal and 
cytoplasmic association with lamellar bodies biogenesis and the period during which 
surfactant first becomes detectable in amniotic fluid 65. The necessity of ABCA3 for LB 
biogenesis is best demonstrated studies by Cheong et al (2007) and Ban et al (2007) in 
which mice targeted with disruption of ABCA3 gene were characterized. The studies 
found that Abca3 homozygous knock-out mice were lethal immediately after birth66,67. 
Measurement of surfactant lipid production via incorporation of radio-labeled substrates 
into newly synthesized PC and other phospholipid species revealed lower levels in 
Abca3-/- mice compared to Abca3+/+ wildtype mice lungs. In assessing whether loss of 
ABCA3 function via genetic knock-out models had interfered with LB biogenesis, 
Cheong et al looked at lungs from E18.5 and E19.5 Abca3+/- heterozygous and Abca3-/- 




Abca3-/- mice. Together, this study indicates that ABCA3 is necessary for LB biogenesis 
and also supports the role of ABCA3 as a surfactant lipid transporter within AEC2s.  
Clinical course and genotype-phenotype correlation of ABCA3 mutations  
 It is believed that respiratory disease associated with ABCA3 mutations is 
inherited in an autosomal recessive manner, evidenced by the lack of lung disease in 
parents who are carriers of ABCA3 mono-allelic mutations. Nevertheless, one study has 
shown deleterious effects some mono-allelic ABCA3 mutations on increased risk of 
neonatal respiratory distress in infants of European or African descent 56. Clinical courses 
of patients with identified recessive ABCA3 mutations vary from neonatal respiratory 
failure to chronic ILD in young children 68. CT scans typically show ground-glass 
opacification, septal thickening, parenchymal cysts and sunken breastbone (pectus 
excavatum). Histological findings from lung biopsies of patients at different ages include 
pulmonary alveolar proteinosis, interstitial widening, and alveolar epithelial hyperplasia 
(Fig 1.3 e). Ultrastructural findings typically reveal smaller lamellar bodies with some 
Fig 1.3 Histopathology of ABCA3 mutant human lung. (e) Lung from a neonate with a lethal ABCA3 mutation, 
exhibiting granular, eosinophilic, alveolar proteinosis material mixed with macrophages. ( f ) EM of an alveolar 
type II cell from a neonate with a lethal ABCA3 mutation, demonstrating abnormally small lamellar bodies (blue 
arrows) with eccentrically placed, electron-dense inclusions and tightly packed phospholipid lamellae. Figure from 




containing eccentric dense bodies (Fig 1.3 f) and fewer overall numbers of lamellar 
bodies in a few patients2,69,70.  
 Diverse clinical course in patients identified with ABCA3 mutations is well 
described in a study by Wambach et al (2014) summarizing the clinical experiences of 
185 infants and children with lung disease identified with recessive ABCA3 mutations. 
According to the study, over 81% of subjects presented with respiratory symptoms at 
birth, 14 % within 1 year of birth, and 5% during childhood (beyond 1 year of age), 
underscoring the predominantly early onset of respiratory symptoms. High mortality and 
morbidity resulting from progressive respiratory failure are apparent through the 1 year 
survival rate of 28% with an additional 10% undergoing lung transplantation and all 
surviving subjects had continued poor growth consistent with failure to thrive beyond 
neonatal period 55.  
 Of the 185 total subjects, 25% were identified with 2 frameshift or nonsense 
mutations predicted to result in null/null genotype; 21% of subjects with one complete 
loss of function mutation and one missense, splice site, or insertion/deletion (null/other 
genotype); and 54% of the subjects had two missense, splice site, or insertion/deletions 
(other/other genotypes). The study also found that 59% of identified ABAC3 mutations 
were compound heterozygous while 41% were homozygous mutations consisting of 
mainly null/null genotypes and a minority other/other genotype. Amongst the commonly 
identified mutations, p.E292V mutation was found to be most commonly associated with 
chILD. Genotype-phenotype correlation revealed the null/null genotypes to result in the 




birth die or undergoing lung transplantation within 1 year of age, highlighting the 
important role ABCA3 plays in lung function. Clinical outcomes of subjects with 
null/other or other/other genotypes were less severe but more diverse and less predictable 
with 72% survival rate after 1 year of age and some surviving into adolescence and 
adulthood. This is most likely due to residual ABCA3 function and much like CFTR, 
another ABC transporter, disease mechanisms can potentially differ between the over 200 
identified ABCA3 mutations based on its location and its impact on the enzymatic 
function of ABCA3. Therefore, augmentation of residual ABCA3 function or targeted 
pharmacological intervention based on improved understanding of ABCA3 mutant-
specific disease mechanism may improve future patient outcome.  
Current disease models of ABCA3 mutations 
Challenges in studying primary AEC2s  
 Evaluating pathogenesis of ABCA3 mutations in a primary cell would be a key 
step to developing mechanism-specific therapeutics. However, studying AEC2 
pathophysiology in primary cells has been challenging due to the lack of proliferation in 
culture and tendency to transdifferentiate into alveolar epithelial type I-like cells 71-74.   
While in silico models of some ABCA3 mutations have correlated with predictable 
clinical outcomes, they fail to predict biological phenotypes for the majority of ABCA3 
mutations 75, necessitating biological disease models for better disease symptom 




Murine models  
 Available mouse in vivo models include ABCA3 knock-out and conditional 
knock-out models resulting in death immediately after birth with after conditional knock-
out of the Abca3 gene 66,67,76, consistent with null/null patients who typically present with 
the most severe clinical outcomes such as neonatal respiratory distress syndrome55. 
Because of these observed phenotypes, current mouse models contribute to the notion 
that the deleterious effects of ABCA3 mutations purely results from the loss of its 
enzymatic function. While this may be true for null mutations, patients with missense 
mutations can have remarkably different disease progressions including pulmonary 
fibrosis and alveolar remodeling long after birth55. Future researched aimed at developing 
new, in vivo mouse models containing relevant point mutations that recapitulate these 
other pathological aspects of the human disease may prove to be a promising 
physiological model to study different types of ABCA3 mutations. 
Cell line disease models 
 In the absence of readily available disease-relevant tissue, recombinant 
overexpression models of wildtype and mutant ABCA3 have been used to study features 
of ABCA3 mutations in heterologous cell lines such the human embryonic kidney cell 
line HEK293 and lung adenocarcinoma cancer cell line A549 75,77,78. While these cell 
lines do not exhibit physiological or functional surfactant metabolism capacities of 
primary AEC2s 79, overexpression of recombinant ABCA3 fused with fluorescent 
reporters resulted in translation of ABCA3 fusion proteins and localization to 




lysosome-derived vesicles, consistent with previous characterizations of LB as a 
lysosomal-derived organelle 80,81. Ultrastructural analysis by electron microscopy (EM) 
revealed these organelles in A549 cells, but not as apparent in HEK293 cells, to contain 
lamellated layers reminiscent of lipid-laden LBs in primary AEC2s75. Based on their 
similarities to endogenous LBs, these organelles have been termed lamellar body-like 
inclusion bodies (LBLIB) 79.  
 To date, a limited number ABCA3 mutations have been studied with these cell 
line models capitalizing on the versatility of fluorescently-tagged ABCA3 fusion 
reporters which have led to a preliminary classification of ABCA3 mutations into two 
subtypes: trafficking (type I) or functional (type II) mutations, highlighting two 
hypothesized disease-causing mechanisms 77,78.  
 Type I ABCA3 mutations include p.L101P, p.L982P, p.L1553P, p.L1591P, 
p.W1142X 77. Expression of these mutant proteins in A549 and HEK293 cells have been 
associated with predominant localization of the mutant protein in the ER instead of 
Fig 1.4 Forced ABCA3 expression in A549 cells. Intracellular immunofluorescent image of A549 cells transfected 
with plasmid expressing wildtype ABCA3:GFP fusion proteins (left, green) , lysosome and lamellar body marker 




LAMP3 or lysotracker+ vesicles 77,82(Fig 1.5). Retention of the mutant protein has been 
hypothesized to be, in part, due to the impaired glycosylation of the translational product 
required for coat complex II-dependent export of the protein from the ER. Impaired 
glycosylation is likely due to disruptions of N-terminal or C-terminal protein folding as a 
result of truncation of the translational product or due to key missense mutations known 
to break a-helical pattern of protein folding such as a number of proline substitutions 
observed in this subclass of mutations.  
 
 Evidence of specific ABC transporter mutations leading to mutant protein 
mistrafficking is well characterized in diseases such as the Tangier's disease (ABCA1) 
and cystic fibrosis (ABCC7/CFTR) whereby the mistrafficking of the mutant transporter 
results in partial or complete loss of function of the transporter. Therefore, these findings 
using cell line models to identify mechanism of disease for ABCA3 mutations may 
Fig 1.5 Subcellular localization of wildtype ABCA3:GFP and mutant proteins in HEK293 cells. (A) Cells 
transiently expressing indicated class II mutant ABCA3:GFP fusion proteins (green) processed for labeling with 
LAMP3 (red)  and merged images. (B) Immunofluorescent images of indicated type I ABCA3 mutations mis-





reflect real disease mechanisms or a real disease mechanism of ABCA3 dysfunction in 
primary cells. 
 Type II mutations include p.N568D, p.G1221S, p.L1580P and in contrast to type I 
mutations, classify a group of mutations that maintains intracellular trafficking but results 
in a functional defect of the transporter. The functional defect of the mutant protein has 
been hypothesized to mainly result from decreased ATP binding or hydrolysis by the 
NBD domains, resulting in decreased transport of phospholipid substrates due to 
defective coupling of ATP hydrolysis to substrate transport. It is hypothesized that 
beyond direct mutations within the NBDs such as in the case of p.N568D mutation, 
mutations in the transmembrane domains of the protein such as p.G1221S can also have 
an effect on the NBD through conformational changes and failure to transduce energy 
from ATP hydrolysis by the NBD 77. 
 In summary, these studies have demonstrated the possibility of distinct subtypes 
of ABCA3 mutations through detailed characterization of mutant protein trafficking and 
functional assays. While these findings may represent real mechanisms of pathogenesis, a 
key limitation of these studies is the use of immortalized or cancer cell lines that do not 
produce functional surfactant 79, raising significant uncertainty as biologically-relevant 
disease models.  
PSC-derived AEC2s to study AEC2 disease 
 To overcome the challenges of studying AEC2 disease due to hurdles in culturing 
and expanding disease-relevant AEC2s, the goal of this dissertation is to develop a 




functional ABCA3 comparable to primary AEC2s. Using this model, we then sought to 
build a disease model to dissect how ABCA3 mutations can disturb normal AEC2 
physiology and lead to the pathogenesis of chILD through functional and transcriptomic 
characterizations.  
 Induced pluripotent stem cells (iPSC) can be generated with ease from patient 
blood or skin samples through exogeneous expression of 4 key transcription factors: 
Oct4, Sox2, Klf4, cMyc 83 and can differentiate, in theory, into any type of mature cell 
84,85, providing new opportunities for in vitro disease modeling in the patient's own 
genetic background. ChILD caused by ABCA3 is an ideal disease to be modeled using 
iPSCs since it is caused by a mutation in a single gene that specifically affects a single 
cell lineage, AEC2s. Moreover, the unlimited proliferative capacity of iPSCs provides an 
inexhaustible source of patient-relevant cells, crucial for the study of a rare disease such 
as chILD. 
Embryonic origin of AEC2s 
 To derive AEC2 in vitro, we begin by summarizing existing knowledge on 
developmental biology of the lung and the embryological origin of AEC2s as a roadmap 
used to derive AEC2s from PSCs. 
 The lung epithelium develops as an outpouching of endodermal gut tube from the 
anterior foregut endoderm. In mice and humans, this outpouching, called the lung bud, is 
defined by the expression of transcription factor NKX2-186 from its SOX2+ esophageal 
primordium along the ventral dorsal axis87. Following this divergence, the NKX2-1+ 




1 primordium is dependent on several key signaling pathways including WNT, 
fibroblastic growth factor (FGF), bone morphogenic protein 4 (BMP), retinoic acid (RA), 
and sonic hedgehog (SHH) pathways (as reviewed in Herriges and Morrisey, 2014) 88.  
 After specification of the lung bud, during the pseudoglandular stage of lung 
development (E10.5-16 in mice, week 5-17 in human), the lung undergoes a highly 
coordinated branching morphogenesis in response to surrounding mesenchymal cues 
such as WNT and FGF signaling, patterning into proximal domains that eventually 
become airway epithelium as well as distal domains that eventually become alveolar 
epithelium (as reviewed in Herriges and Morrisey, 2014). Starting at this stage, SOX9+ 
cells making up the tip of these branching lung buds and begin to adopt expression of 
distal lung and AEC2 markers including expression of the SFTPC locus in E10.5 mice 
and week 12-15 in humans 89.  
 During the canalicular stage of lung development E16.0-17.5/week 16-26), acinar 
structures comprised of respiratory bronchioles and alveolar ducts form, followed by 
invasion of capillaries into the mesenchyme and surrounding the epithelium (as reviewed 
in Rawlins, 2011) 90. Towards the end of the canalicular stage, flattened cells resembling 
type I alveolar epithelial cells (AEC1) become more apparent in addition to cuboidal 
AEC2s (as reviewed in Schittny, 2017) 91. Also during this time, AEC2 upregulate 
expression of genes related to surfactant metabolism including SFTPC, ABCA3, 
NAPSA, LPCAT1 and begin to produce surfactant measurable in the amniotic fluid 
produced by the fetus92. During the saccular stages (E17.5-birth/week 26-36) and alveolar 




separated into smaller units to form over 300 million alveoli, drastically expanding the 
surface area over which gas exchange can occur 93.  
Deriving AEC2-like cells from human PSCs 
 In mice and humans, AEC2s are one of the last cell types to fully mature in 
response to the first exposure to air, continuing to proliferate and increase surfactant 
production after birth. Recapitulating the roadmap to derived AEC2s in vitro, therefore, is 
challenging and includes the entire breadth of fetal development. Early attempts at 
deriving AEC2s from mouse or human PSCs included culture media supplemented with 
serum or conditioned media from a lung adenocarcinoma cell line94, and relied singularly 
on SFTPC mRNA expression to define PSC-derived AEC2s without comparisons to 
primary AEC2 controls 95. Since these early studies, significant progress has been made 
in deriving cells resembling primary AEC2s from human embryonic stem cells (ESC) 
and iPSCs 96-99. These methods recapitulate cues from in vivo mouse and human lung 
developmental biology to generate AEC2-like cells in a process termed "directed 
differentiation" (Keller 1993, Murry and Keller 2008).  
 Directed differentiation begins by recapitulating gastrulation during which 
migration of the epiblast cells through the primitive streak gives rise to the three germ 
layers, including endoderm from which the lung is derived. Derivation of definitive 
endoderm from PSCs is well established; Tgfb (Activin/Nodal) signaling agonists 100-102, 
promote the differentiation of ESCs and iPSCs into definitive endoderm cells detectable 
by Bry+/Foxa2hi cells or by Ckit/Cxcr4 expression 103-105. While researchers rapidly 




mid- and posterior gut tube including intestinal, hepatic and pancreatic cells 103,106,107, 
methods to derive NKX2-1+ thyroid or lung progenitors were not developed until Green 
et al. (2011) described the necessity for the inhibition Tgfb and Bmp4 for brief periods to 
specify anterior foregut endoderm 108. Through the use of fluorescent reporters for 
NKX2-1, early studies were able to define various combinations of Fgf, Wnt, Bmp4, Egf, 
and retinoic acid in serum-free medias to derive human and mouse lung or thyroid 
progenitors from PSC-derived anterior foregut endoderm 109-111.  
 Since the establishment of methods describing efficient generation of NKX2-1+ 
lung progenitor cells 108,109,111, renewed efforts to derive AEC2s from human PSC-
derived NKX2-1+ lung progenitor cells in a 3D culture system identified CHIR (a WNT 
signaling agonist), KGF, and DCI (dexamethasone, cyclic AMP, IBMX) as key factors 
97,98,108), aided, in-part, by the use of knock-in fluorescent reporters for SFTPC 97-99 and 
comparisons to pure populations of primary AEC2s. Functional characterizations of these 
SFTPC+ putative AEC2s revealed lamellar bodies, processing of mature surfactant 
proteins, and secretion of pulmonary surfactant, features shared by mature primary 
AEC2s 97,99(Fig 1.6) and global transcriptomic comparison with primary AEC2 revealed 







Fig 1.6 Human PSC-derived AEC2s. (A) Day 30 Human PSC-derived epithelial spheres expressing 
SFTPCtdTomato reporter (left) plastic sectioned and stained with toluidine blue (right). Arrows indicate cells with 
putative lamellar bodies. gl, glycogen lake. (B)TEM of the same cells showing lamellar body-like inclusion 







 In summary, stage-dependent addition of key growth factor cocktails mimicking 
in vivo lung developmental milestones from the definitive endoderm through activin 
signaling, anterior foregut endoderm through Tgfb and Bmp4 inhibition, and induction of 
NKX2-1+ lung progenitors by WNT, BMP4, and retinoic acid signaling, followed by 
differentiation into distal lung epithelium by WNT, KGF, and steroids, we are now 
capable of deriving these AEC2-like cells, termed induced AEC2s (iAEC2s) that not only 
share physiological, functional, and ultrastructural features of primary AEC2s but also 
resemble primary cells through global transcriptomic analyses. 
Patient iPSC-derived AEC2 modeling of genetic alveolar disease  
	 The ability to derive AEC2s from human PSCs have enable researchers to 
investigate a variety of genetic lung diseases caused by AEC2s previously only studied in 
the setting of non-physiological cell line models.  
 In a previous study from our lab, Jacob et al (2017) demonstrated the use of 
reprogrammed patient fibroblasts containing homozygous SFTPB121ins2 mutation to study 
surfactant protein B deficiency. Clinically, the SFTPB121ins2 mutation is predicted to result 
in premature termination of the translational product accompanied with loss of SFTPB 
protein expression, misprocessing of pro-SFTPC protein, inability to form mature 
lamellar bodies, and failure to synthesize surfactant 47,112. Upon differentiation of these 
patient iPSCs into iAEC2s,  Jacob and colleagues were able to recapitulate these clinical 
phenotypes including the absence of SFTPB protein expression, misprocessing of pro-




corrected using footprint-free CRISPR/Cas9 gene correction, the iAEC2s regained the 
ability to express and process mature SFTPB and SFTPC proteins and formed mature 
lamellar bodies.  
 In another study by Korogi et al (2019), researchers used patient-specific iAEC2s 
to study Hermansky-Pudlak Syndrome (HPS), an autosomal recessive disorder 
characterized by dysfunction of lysosome-related organelles, such as LBs 113. Using their 
patient iAEC2s and syngeneic gene-corrected control iAEC2s, Korogi et al demonstrated 
in their disease model that the diseased iAEC2s can recapitulate previously identified 
features of HPS including altered distribution, enlargement, and impaired secretion of 
LBs. 
 Most recently, research from our lab using the iAEC2 model to study the non-
brichos SFTPC mutation I73T have also recapitulated clinical findings and in vivo mouse 
models including SFTPC protein misprocessing, mistrafficking of the mutant protein to 
the cell membrane instead of LBs, and upregulation of autophagic pathways 
(Alysandratos et al., manuscript in preparation).  
 In summary, multiple recent studies have now demonstrated the feasibility of 
generating patient iPSCs-derived AEC2s, and the utility of using these cells to study 
patient- and mutant-specific phenotypes in diseases related to surfactant dysfunction 98 
and Hermansky-Pudlak Syndrome 113,114.   
Hypothesis and aims 
 In this dissertation, we first propose to establish a human pluripotent stem cell 




surfactant metabolism and ABCA3 protein function. Then, we will employ this model 
using ABCA3 mutant patient-specific iPSC lines to study the effect of ABCA3 mutations 
spanning two hypothesized disease mechanisms in AEC2s. Completing these aims will 
provide an opportunity to model alveolar diseases using a primary-like cell derived from 
actual patients. In doing so, we hope to identify ABCA3 mutant-specific disease 
mechanisms which will be the first step to developing effective in vitro screens to 
discover the first mechanism-based therapeutics for chILD patients.  
  I hypothesize that ABCA3 mutations cause AEC2 dysfunction and lung disease 
due to two major pathological mechanisms, both of which can be interrogated in our 
patient-specific iPSC-derived disease model: (1) mutations in the transmembrane domain 
of the ABCA3 protein leading to misfolding, mistrafficking, and upregulation of ER 
stress responses and AEC2 apoptosis, and (2) loss of function in the hydrolysis domain of 
the ABCA3 protein resulting in dysfunctional AEC2 surfactant processing and decreased 
surfactant phospholipid secretion. I test my hypothesis through 2 specific aims:  
 Aim 1: Create a novel, pluripotent stem cell-based, in vitro bi-fluorescent model 
system to investigate the expression, trafficking, and function of normal ABCA3 in 
pluripotent stem cell-derived AEC2s (iAEC2s). Using gene editing technology, I have 
targeted a Tomato fluorochrome reporter into the surfactant protein C (SFTPC) locus, a 
marker of distal lung progenitor and AEC2s, and an ABCA3:GFP fusion reporter into the 
ABCA3 locus in a human PSC line allowing for identification and isolation of a subset of 
SFTPC+ iAEC2s that express ABCA3. Using this bi-fluorescent line, I will define the 




differentiate into functional lamellar body-expressing iAEC2s. I will then characterize 
ABCA3-dependent surfactant lipid transporting function by assessing secreted levels of 
surfactant phospholipids compared to primary AEC2 controls using lipidomic analysis.  
 Aim 2: Identify the downstream effects of ABCA3 mutations on AEC2 function 
and phenotype using patient-specific iAEC2s. I will next utilize patient-derived iPSCs 
containing homozygous mutations in the ABCA3 gene spanning the two hypothesized 
classes of trafficking and hydrolysis ABCA3 mutations, thus creating a reductionist 
disease model in a patient-specific genetic background. Using these iPSCs vs syngeneic 
gene-corrected iPSCs, I will assess ABCA3 protein localization, surfactant protein and 
lipid processing, global transcriptomic perturbations, and effects on stem cell function 







CHAPTER 1: A PSC-DERIVED AEC2 MODEL TO STUDY ABCA3 BIOLOGY 
 Difficulties in culturing primary human AEC2s have posed significant hurdles to 
investigating diseases that arise from AEC2s, resulting in reliance on rodent primary cells 
or human carcinoma cell line models with uncertain physiological relevance to 
recapitulating human diseases. To overcome the challenges of working with primary 
AEC2s, recent studies, including Jacob et al (2017, 2019) from our lab, have described 
methods to derive primary-like AEC2s in vitro from human PSCs, termed induced 
AEC2s (iAEC2s) 97,98,115, with a possibility to serve as an inexhaustible source of 
accessible AEC2s to researchers. Transcriptomic and functional comparisons with 
primary AEC2s from our lab have revealed that iAEC2s not only express genes essential 
for surfactant metabolism, including ABCA3, but also are capable of synthesizing and 
secreting pulmonary surfactant 97. Despite evidence of ABCA3 mRNA expression, at the 
beginning of my dissertation work, there was no evidence that ABCA3 protein was 
expressed in iAEC2s. Additionally, there was uncertainty regarding whether the human 
ABCA3 protein would behave similarly to those characterized in murine or human cell 
line models. Functional ABCA3 protein expression within iAEC2s would not only 
confirm previous research in a physiologically relevant human cell type, but would also 
serve as a foundation to assess whether the iAEC2 platform can serve as a disease model 
to recapitulate changes in iAEC2 physiology as a result of ABCA3 mutations (second 




 A challenge in confirming human ABCA3 protein expression, even in primary 
human AEC2 samples, is the lack of commercially available antibodies and the lack of 
cross-species reactivity for antibodies raised against murine ABCA3. To overcome this 
technical limitation, for the first half of my dissertation work, I designed an ABCA3 
endogenous knock-in fluorescent fusion reporter, enabling not only the identification of 
iAEC2s expressing ABCA3 protein, but also intracellular imaging of the ABCA3 fusion 
protein to study its localization within iAEC2s. Work described in this chapter details 
characterization of the ABCA3:GFP reporter by assessing its specificity and sensitivity, 
whether the reporter enriches for other key AEC2 genes, and how the fusion reporter 
traffics within iAEC2s. Moreover, since ABCA3 is specifically expressed in AEC2s 
within the lung in vivo, we explored the utility of the ABCA3:GFP reporter as an AEC2-
specific reporter compared to the previously described SFTPCtdTomato reporter. In doing 
so, we discovered heterogeneous populations of iAEC2s defined, in part, by their 
differences in levels of AEC2 gene expression and proliferation. The results summarizing 
these findings are explained below as a manuscript in preparation titled: "Heterogeneity 
in human iPSC-derived alveolar epithelial type II cells revealed with bi-fluorescent 
ABCA3/SFTPC reporters". 
Rationale 
 Alveolar type II epithelial cells (AEC2s) are the facultative progenitors of lung 
alveoli as they maintain the alveolar epithelium through self-renewal or differentiation 
into alveolar type I epithelial cells (AEC1s) 27,116,117. AEC2s also serve important 




alveolar surface tension. Mutations in genes highly expressed within AEC2s such as 
SFTPC, ABCA3, or SFTPB can result in pediatric interstitial lung disease and neonatal 
respiratory distress 2,11,21,47,69, emphasizing a key role for AEC2s in distal lung 
homeostasis. However, uncovering the mechanisms describing the inception of disease in 
AEC2s has been hindered by limited accessibility to primary and patient-specific disease-
relevant cells and difficulties in maintaining the AEC2 phenotype in vitro118,119.  
 Adding complexity to the study of AEC2s is the recent realization that both the 
fetal and adult AEC2 populations in mice appear to be heterogeneous with AEC2 subsets 
that appear to be more proliferative and more responsive to Wnt signals 120-122. In mouse 
development there also appears to be a gradient of SFTPC expression that identifies less 
mature developing AEC2 progenitors compared to more mature AEC2s that express 
higher levels of all surfactants, including SFTPC, based on single cell RNA sequencing 
profiles 123. These recent findings raise questions about whether similar heterogeneity 
also exists in human AEC2s 121 and their possible roles during lung development and 
repair after injury. 
 To begin to address human AEC2 heterogeneity as well as the putative role of 
AEC2s in disease pathogenesis, our lab and others have derived primary AEC2-like cells 
(iAEC2s) in vitro from human pluripotent stem cells (PSCs) 97-99, using directed 
differentiation toward a distal lung fate. Directed differentiation in vitro emulates key in 
vivo lung developmental milestones, and can be monitored by the use of knock-in 
fluorochrome reporters such as NKX2-1GFP 109 and SFTPCtdTomato 97,98,124 that identify the 




alveolar epithelium 97,98. Differentiation of PSC lines containing these reporters gives rise 
to a population of NKX2-1GFP/SFTPCtdTomato double positive cells that are 
transcriptionally similar to primary adult AEC2s with some cells having lamellar bodies 
that process and secrete surfactant protein and phospholipid 97,98. 
 While the SFTPCtdTomato reporter has facilitated the isolation of cells, some of 
which are similar to adult primary AEC2s, SFTPC mRNA is also expressed in the 
developing lung in the distal lung bud tip as well as in AEC2s 126,127, complicating the 
identification of maturing AEC2s from a heterogeneous population of developmental 
progenitors. Other potential AEC2 markers include NKX2-1, and SFTPB both of which 
are also expressed in other lung epithelial lineages, while genes such as PGC and LYZ 
are highly expressed in mature AEC2s but are also expressed in non-lung endodermal 
tissues such as the stomach, undermining their utility as specific AEC2 markers. 
 The ATP binding cassette A3 (ABCA3) is a promising candidate as a more stage 
and lineage specific marker due to its AEC2-specific expression within the adult lung and 
expression later in fetal lung development, detected after week 28 of gestation63, 
compared to SFTPC at week 15126. Functionally, ABCA3 protein is localized to the 
limiting (outer) membranes of lamellar bodies, where it serves as the major transporter of 
surfactant lipids. Combined with its later onset of expression in the developing lung, 
ABCA3’s critical role in surfactant metabolism as well as its protein localization pattern 
presents an opportunity to engineer a fusion reporter enabling the visualization of 





 Here, we address the question of AEC2 cellular heterogeneity and maturation in 
our human pluripotent stem cell derived distal lung epithelial in vitro model system by 
engineering combinatorial reporter systems to identify and isolate distinct populations of 
PSC-derived AEC2s for transcriptomic and functional characterizations. We first conduct 
single cell RNA sequencing (RNA-seq) on PSC-derived distal lung epithelial cells 
containing NKX2-1 and SFTPC bi-fluorescent reporters, revealing two transcriptionally 
similar AEC2 populations expressing similar levels of most canonical AEC2 genes, 
including ABCA3, but different levels of SFTPC and proliferative genes. We find a 
gradient of SFTPC mRNA expression in iAEC2s where only those iAEC2s expressing 
the highest levels of the SFTPC locus express the SFTPCtdTomato reporter. To encompass 
the cells that seemingly shared the AEC2 program missed by SFTPC reporter, we 
developed a new ABCA3:GFP fusion reporter which localizes GFP to the limiting 
membrane of intracellular vesicles reminiscent of lamellar bodies in PSC-derived AEC2s 
following distal lung differentiation. Using the new ABCA3 fusion reporter in 
conjunction with the SFTPC reporter to distinguish AEC2-like cells from other lung 
epithelial lineages, we first observed delayed onset of ABCA3 expression compared to 
SFTPC followed by emergence of distinct populations of cells expressing both reporters 
as well as a larger population singularly expressing ABCA3 characterized by lower levels 
of some AEC2 maturation markers. While both reporter populations functionally 
processed surfactant proteins, the ABCA3 single positive population expressed higher 
levels of transcripts associated with proliferation, faster growth kinetics, and increased 




are a heterogeneous population of cells with differing proliferative and maturation 
properties. 
Methods 
Human PSC Reporter Line Generation and Maintenance 
 The BU3 human iPSC line was previously generated in Kurmann et al (2015). 
Reporter targeting strategies of the BU3 human iPSC line with the NKX2-1GFP reporter 
are detailed in Hawkins et al. (2017) and SFTPCtdTomato reporter are detailed in Jacob et 
al. (2017), resulting in the final bi-fluorescent BU3 NKX2-1GFP/SFTPCtdTomato line (BU3-
NGST) 97,98,124. Targeting of the RUES2 human ESC line (a generous gift of Dr. Ali 
Brivanlou, Rockefeller University) with the SFTPCtdTomato reporter to generate the 
RUES2-ST reporter line was also previously described in Jacob et al (2017). 
 All PSCs were cultured on Matrigel-coated (Corning cat #354277) plates in 
mTeSR media (StemCell Technologies, cat# 85850).  
Generation of Knock-in ABCA3:GFP Human PSC Reporter System for Isolation of 
Alveolar Epithelial Type 2-like Cells 
 To target the endogenous ABCA3 locus, a guide/Cas9 plasmid (pSpCas9(BB)-2A-
GFP(PX458), Addgene, plasmid no. 48138) was engineered to contain guide RNA 
sequence 5’ CCGCAGAGGAGGGGCGATGA 3’ to recognize the stop codon of the 
endogenous ABCA3 gene (Ran et al., 2013), called pU6-ABCA3_gRNA1-SpCas9-2A-
GFP. To generate the donor template, 700bp of homology arms directly upstream and 




genomic DNA. Next, using molecular cloning techniques, the ABCA3 left and right 
homology arms were inserted into the phACTA2_HL-P2A-eGFP-PGK-PuroR-
hACTA2_HR donor plasmid while eliminating the previous hACTA2 homology arms 
(Kwong et al, 2019) followed by elimination of the P2A sequence. The resulting final 
donor vector, called pABCA3_HL-eGFP-PGK-PuroR-ABCA3_HR (Figure 2A, plasmid 
map available at www.kottonlab.com),containing floxed puromycin resistance gene 
enabled chemical selection of targeted cells.  
 To transfect CRISPR/Cas9 guides and donor to PSCs, between 50-70% confluent 
plate of BU3 or RUES2-ST PSCs were dissociated into a single cell suspension with Gentle 
Cell Dissociate Reagent (StemCell Technologies, cat. no. 07174). 5X106 cells were 
resuspended in P3 and Supplement solutions containing 3ug of donor template vector and 
2µg of gRNA/Cas9 plasmid (Lonza, cat. no. V4XP-3024), nucleofected using program 
CB-150 in the 4D-Nucleofector X System (Lonza), and plated on Matrigel-coated plates 
in mTeSR containing 10µM ROCK inhibitor (RI, R&D Systems, cat. no. 1254) for 1 day 
at which point media was changed to mTeSR without ROCK inhibitor for 5 days for colony 
outgrowth. On day 6 after nucleofection, 5 days of chemical selection using 700ng/ml 
puromycin (ThermoFisher Scientific, cat. no. 11811023) was conducted and surviving 
colonies were assayed for homologous integration using two primer pairs: F: 5’ 
GGAATTCAGTGTAAAACAGGAAAGGG 3’ R: 5’ TTGCTCACCATGACCGGTCG 
3’ for 5’ integration and F: 5’ TCAGCAGCCTCTGTTCCAC 3’ R: 5’ 
ACGTTGTAAAACGACGGCC 3’ for 3’ integration. Bi-allelic targeting of the donor 




TTGTAATCTGAGCTGGGAACAGC 3’ R: 5’ TGGTCACAACGTATTCAATGTGTCC 
3’, generating a 1148bp product for an untargeted allele and a 3970bp product for a targeted 
allele. 
 The floxed puromycin resistance cassette was excised in successfully targeted 
clones by transient transfection of a plasmid expressing Cre-recombinase (pHAGE2-
EF1aL-Cre-IRES-NeoR-W; plasmid map available at www.kottonlab.com) using 
Lipofectamine LTX (ThermoFisher, cat. no. 15338100), followed by selection with 
200ug/ml Geneticin (ThermoFisher, cat. no. 11811023) for 5 days. Excision was confirmed 
by cell death with 700ng/ml puromycin treatment as well as by PCR using screening 
primers for the puromycin resistance cassette F: 5’ ATGACCGAGTACAAGCCCACG 3’, 
and R: 5’ TCAGGCACCGGGCTTGC 3’. Normal karyotypes of successfully targeted, cre-
excised clones were confirmed by G-banding analysis (Cell Line Genetics, Madison, WI). 
The two final human PSC lines generated using this targeting methodology include the 
BU3 ABCA3:GFP human iPSC line (BU3-AG), and the bi-fluorescent RUES2 
SFTPCtdTomato ABCA3:GFP human ESC line (RUES2-STAG).  
Directed Differentiation of Human PSCs to Distal Lung Epithelium 
 To derive distal lung epithelial cells, pluripotent stem cells were first dissociated 
into single cells suspension and 1.8-2X106 cells were plated per well of a 6-well tissue 
culture plate coated with Matrigel for 24 hours in mTeSR media containing ROCK 
inhibitor (RI) prior to differentiation into definitive endoderm differentiation using the 
Definitive Endoderm Kit (Stem Cell Technologies) for 3 days (day 0-3). To drive 




plate in complete serum free differentiation medium (cSFDM) containing IMDM 
(ThermoFisher), Hams’s F12 (ThermoFisher), B27 (Thermo Fisher), N2 (Thermo fisher), 
ascorbic acid (Sigma Aldrich), monothioglycerol (Sigma Aldrich, St. Louis, MO), bovine 
albumin fraction V (ThermoFisher), and Glutamax (Thermo Fisher) supplemented with 
2µM of dorsomorphin (Stemgent, Lexington, MA) and 10µM SB431543 (DS/SB) for 3 
days (day 3-6) plus 10µM RI for the first 24 hrs. On day 6, cells were re-fed with cSFDM 
media supplemented with 3µM CHIR (Biotechne, Minneapolis, MN) 100nM retinoic 
acid (Sigma-Aldrich), and 10ng/mL rhBMP4 (BioTechne) for specification of lung 
lineage. 
 On day 14-16, cells were single-cell dissociated by trypsin for fluorescence 
activated cell sorting to enrich for NKX2-1 expressing lung epithelial progenitors using 
antibodies against cell surface markers CD47/CD26 as described in Hawkins et al. 
(2017), re-plated in 3D Matrigel (Corning) in the concentration of 300-500 cells/µl and 
fed with distal lung differentiation media containing CK+DCI medium described in Jacob 
et al. (2017, 2019), containing RI for the first 72 hours then subsequently re-fed with 
CK+DCI medium every other day onward. 
 Alveolospheres were passaged every 2 to 3 weeks by dissociating 3D matrigel 
using 2mg/mL dispase (Thermo Fisher cat. no. 354235) followed by single-cell 
dissociation using trypsin and re-plated in 3D matrigel as described above and in Jacob et 
al. (2017, 2019), Hawkins et al. (2017), Hurley et al. (2020).  
 Retention of lung epithelial identity was confirmed by flow cytometry analysis of 




Flow Cytometry and Cell Sorting 
 Preparation of single-cell suspension for flow cytometry and cell sorting are 
described as above. Prepared samples were either directly sorted on knock-in reporter 
expressions (ABCA3:GFP, SFTPCtdTomato, both, or neither reporters) on the MoFlo 
Astrios Cell Sorter (Beckman Coulter, Indianapolis, IN) or stained with indicated 
relevant primary and secondary antibodies prior to cell sorting (more below). 
 Staining of cells in single-cell suspension for CPM and SLC34A2 surface 
antigens for flow cytometry and cell sorting were done on ice using primary mouse 
monoclonal antibodies against human CPM (Fujifilm Wako, cat. no. 014-27501, 1:200) 
and SLC34A2 (MX35, a gift from Dr. Gerd Ritter, Memorial Sloan Kettering, 1:200) for 
30min and subsequently stained with secondary Alexa Fluor 647 conjugated antibody 
(Thermo Fisher cat. no. A32787, 1:500) for another 20 min. 
Immunofluorescence and Confocal Microscopy of iAEC2s and Primary AEC2s 
 Routine live-cell immunofluorescence imaging of PSC-derived alveolospheres 
was conducted using Keyence BZ-X800 microscope (Keyence, Osaka, Japan).  
 For wholemount staining, alveolospheres (in 3D culture) were harvested by 
treatment with 2mg/ml of dispase for 30 minutes to one hour at 37 oC, fixed with 4% 
paraformaldehyde (ThermoFisher, cat. no. 28908), permeablized with 0.5% Triton-X100 
(Sigma-Aldrich, cat. no. 9002-93-1), and blocked with 4% serum for one hour and 
stained with primary antibodies: chicken anti-GFP (ThermoFisher, cat. no. A10262, 
1:500); mouse anti-CD63 (LAMP3, Diaclone, cat. no. 857.770.000, Besançon, France, 




fluorophore-conjugated secondary conjugated antibodies (ThermoFisher, 1:500), Hoechst 
stain (ThermoFisher, 1:500) and imaged using Zeiss LSM 700 confocal microscope 
(Zeiss, Oberkochen, Germany). 
 Immunofluorescence staining on 4% paraformaldehyde (PFA) fixed, OCT 
protected frozen human lung was performed on 7µm thick frozen tissue sections. Slides 
were rehydrated in PBS, fixed in 4% PFA, and washed in PBS. Antigen retrieval was 
performed in 0.1 M citrate buffer (pH 6.0) by microwaving. Slides were blocked for 2 
hours at room temperature using 4% normal donkey serum in PBS containing 0.2% 
Triton X-100, and then incubated with primary antibodies diluted in blocking buffer for 
approximately 16 hours at 4°C. Primary antibodies included mouse ABCA3  (1:100, 
Seven Hills Bioreagents) and  rabbit ABCA3  (1:100, Seven Hills Bioreagents). 
Secondary antibodies conjugated to Alexa Fluor 488 or Alexa Fluor 568 were used at a 
dilution of 1:200 in blocking buffer for 1 hour at room temperature. Nuclei were 
counterstained with DAPI (1µg/ml) (Thermo Fisher). Sections were mounted using 
ProLong Gold (Thermo Fisher) mounting medium and coverslipped. Tissue sections 
were then imaged on an inverted Nikon A1R confocal microscope using a NA 1.27 
objective using a 1.2 AU pinhole. Maximum intensity projections of multilabeled Z stack 
images were generated using Nikon NIS-Elements software. 3D images were generated 
using Imaris software (Bitplane). 
SFTPB and ProSFTPC Western Blot Analysis 
 Pure, sorted populations of cultured cells were treated with lysis buffer (RIPA 




min. Cell debris was cleared by centrifugation at 15,000g for 20min and supernatants 
were harvested. Sample protein concentrations were measured using Bio-Rad DC Protein 
Assay. 10µg of lysate from each sample was resolved on pre-cast 10%NUPAGE gels 
(Thermo Fisher) and transferred to PVDF membrane (Bio-Rad). Blots were incubated 
with primary antisera containing of either surfactant protein B (PT3, rabbit polyclonal 
antibody against bovine mature SP-B; Beers et al., 1992; 1:3000 dilution) or NPRO-
SFTPC (dilution 1:300, Beers et al., 1994), b-actin (dilution 1:1000, Sigma). Species-
specific secondary antisera were all conjugated to IR dyes of either 680 or 800 nm 
wavelengths (Rockland) at a dilution of 1:10000. Visualization was accomplished using 
the Odyssey Imaging System (LiCOR Biosciences). 
Electron Microscopy 
Fixation and preparation of alveolosphere for imaging using CM12 Transmission 
Electron Microscope (Philips) were performed as described previously in Jacob et al. 
(2017).  
Quantitative Reverse Transcriptase PCR 
 qRT-PCR was performed as previously described in Hawkins et al (2017). 
Briefly, RNA was harvested following manufacturer's instructions using Qiazol and 
miRNeasy mini kit (QIAGEN). cDNA was generated by reverse transcription of 100ng 
RNA from each sample using Applied Biosystems High-Capacity cDNA Reverse 
Transcription Kit. For qPCR, either 20µl reactions (for use in Applied Biosystems 




QuantStudio7 384-well System) were prepared using 2µl of diluted cDNA and run for 40 
cycles. All primers were TaqMan probes from Applied Biosystems (specific primer cat. 
no. referenced in Jacob et al., 2017). Relative expression was calculated by average cycle 
value (Ct) of samples normalized to 18S control, and reporter as fold change (2-DDCt), with 
fold change of 1 assigned to day 0 undifferentiated PSCs.  
RNA Sequencing  
 For the two bulk RNA sequencing experiments comparing (1) day 31 BU3 
ABCA3:GFP+, GFP- cells and (2) day 36 RUES2 STAG DP, SP, DN cells, following 
cell sorting for desired cell population, biological triplicate (n=3) samples of purified 
RNA was harvested using the same method described above using Qiazol (QIAGEN). 
RNA Sample Preparation Kit v2. mRNA was isolated using magnetic beads-based 
poly(A) selection, fragmented, and randomly fragmented for reverse transcription, 
followed by synthesis of cDNA fragments. cDNA fragments were then end-paired, and 
ligated to Illumina Paired-End sequencing adapters. The products were end-paired and 
PCR-amplified to create the final cDNA library. Sequencing of pooled libraries were 
done using NextSeq 500 (Illumina). 
 For single cell RNA sequencing of day 33 BU3 NGST cells, following live-cell 
sorting of desired NKX2-1GFP single positive and NKX2-1GFP/SFTPCtdTomato double 
positive populations. Single cells were captured on the Fluidigm C1 chip with automated 
microfluidic system followed by cell lysis, reverse transcription, and cell multiplexing in 
an integrated fluidic circuit chip. Final cDNA library was pooled and sequenced using the 




iAEC2 EdU and Colony Formation Assays 
 To assess active DNA synthesis as a measurement of cell proliferation, cellular 
incorporation of 5-ethynyl-2’-deoxyuridine (EdU) was evaluated using the Click-iT EdU 
Alexa Fluor 647 Flow Cytometry Assay Kit (Invitrogen, cat. no. C10419). 
Alveolospheres expressing a heterogeneous population of SFTPCtdTomato and 
ABCA3:GFP reporters were plated at a concentration of 400 cells/µl in 3D Matrigel in 
CK+DCI medium. 12 days after plating, EdU was added to the alveolospheres at a 10 µM 
final concentration for 24 hours. The spheres were subsequently dissociated and sorted 
into three separate populations on a MoFlo Astrios cell sorter (Beckman Coulter, CA, 
USA): ABCA3:GFP single positive (SP) cells, SFTPCtdTomatoABCA3:GFP double 
positive (DP) cells, reporter double negative (DN) cells. The cells were fixed, 
permeabilized, and stained with the Click-iT reaction mixture according to the 
manufacturer’s protocol. The percentage of SP, DP, and DN cells that incorporated EdU 
was determined by flow cytometry (Stratedigm, CA, USA). 
 
Results 
Directed differentiation of distal lung epithelium from hiPSCs results in heterogeneous 
cell populations expressing a gradient of SFTPC mRNA  
 To profile the heterogeneity of distal lung epithelial cells arising from hPSC in an 
in vitro human distal lung differentiation, we differentiated a human iPSC line containing 
NKX2-1GFP and SFTPCtdTomato reporters (referred to as BU3 NGST) using our previously 




putative lung primordial progenitors 109 by flow cytometry and re-plated this population 
in 3D Matrigel in the presence of a medium97 designed to promote distal alveolar 
epithelial differentiation (Fig 2.1A). Consistent with our prior publications 97,98,124 
monolayered epithelial spheres emerged from the sorted cells, and NKX2-
1GFP/SFTPCtdTomato double positive cells were first detectable 48 hours later (17 days total 
differentiation time). By day 33 of differentiation, these cells comprised 4.5% of the total 
population. GFP+/tdTomato+ cells represented a subset of the 68% NKX2-1GFP+ cell 
population at this time point (Fig 2.1B), suggesting heterogeneity in the population of 
putative lung epithelial (NKX2-1+) cells generated by this approach.  
 To determine the transcriptional differences between the NKX2-
1GFP/SFTPCtdTomato double positive and NKX2-1GFP single positive cell populations, we 
sorted pure cells from each population for single cell RNA sequencing (scRNA-seq). 
Analyses of sequencing data revealed 147 differentially expressed genes between the two 
populations but no distinct clustering by UMAP dimensionality reduction analysis (Fig 
2.1C, absolute log2FC> 1, FDR<0.05) with SFTPC being the top upregulated gene in the 
NKX2-1GFP/SFTPCtdTomato double positive population (Fig 2.1D). Although differentially 
expressed, this canonical transcript of AEC2 identity was detectably expressed in both 
populations suggesting that both populations likely contained distal lung epithelium.  
Consistent with this likelihood, additional AEC2 genes were detectably expressed at 
similar levels between the two populations, including NKX2-1, LPCAT1, CTSH, PGC, 
ETV5, MUC1, LAMP1, NAPSA, ABCA3 and SFTPB (Fig 2.1D). A subset of these 




SFTPB, CTSH, and the AEC2 maturation marker PGC124 (Fig 2.1D). In the NKX2-1GFP 
single positive population, upregulated genes were those associated with cell division and 
DNA synthesis including TOP2A, MKI67, CENPF, CDC25A, MCM3, and (Fig 2.1E). 
These results suggested a shared AEC2 program in both populations with the NKX2-1GFP 
single positive population comprising a potentially less mature and more proliferative 










ABCA3 knock-in GFP fusion reporter enables isolation and tracking of iAEC2s and 
visualization of lamellar bodies 
 Since the AEC2 transcript ABCA3 exhibited shared expression in both NKX2-
1GFP+ and NKX2-1GFP+/SFTPCtdTomato+ populations (Fig 2.1 D) and ABCA3 protein 
function is required for lamellar body biogenesis, we speculated that visualization of 
ABCA3 protein might serve to identify iPSC-derived AEC2s in our model system with 
higher sensitivity than our SFTPCtdTomato reporter. We also hypothesized that tracking 
localization of ABCA3 protein beyond the transcript level might facilitate the monitoring 
of AEC2 functional maturation, since ABCA3 is both a canonical identity gene in AEC2s 
66,128  and a required surfactant phospholipid transporter known to localize to the limiting 
membrane of lamellar bodies in mature AEC2s62,66,67,128.  
 To generate a new iPSC line carrying an ABCA3 reporter that simultaneously 
enables the visualization of its intracellular trafficking pattern in the absence of a robust, 
commercially available human ABCA3-specific antibody, we employed CRISPR/Cas9 
gene editing tools to insert a knock-in GFP reporter at the stop codon of the endogenous 
ABCA3 locus in our published normal human BU3 iPSC line 109 and in the human 
embryonic stem cell (ESC) line, RUES2 97, resulting in an ABCA3 translational product 
that is fused to the GFP protein (hereafter ABCA3:GFP; Fig 2.2A) allowing for not only 
temporal assessment of ABCA3 protein expression during directed differentiation into 
iAEC2s, but also its intracellular localization. We differentiated BU3 iPSCs containing 
the ABCA3:GFP fusion reporter (hereafter BU3-AG) in our protocol promoting distal 




cells expressing ABCA3:GFP within monolayered epithelial spheres (Fig 2.2C). We 
quantified GFP expression kinetics, with first onset visualized around day 22 and 
detectable by flow cytometry in 8.95% ± 0.87% of all cells by day 31(Fig. 2.2I). By high 
resolution confocal microscopy, we found that the ABCA3:GFP fusion protein localized 
to cytoplasmic vesicles, which co-stained with the lamellar body (LB)-associated marker, 
LAMP3 (Fig. 2.2D, E), reminiscent of ABCA3’s endogenous localization to LBs in 
primary AEC2s of an 8 year old human lung (Fig. 2.2F). Notably, the ABCA3:GFP+ 
vesicles appeared to localize to the apical end of each cell towards the lumens of these 
spheres, a possible indication of the presence of mature LBs poised for exocytosis into 
the alveolar lumen. Further imaging using toluidine blue staining for lamellar bodies 
revealed LBs in the sphere lumen (Fig 2.2G). Electron micrographs of BU3 AG-derived 
spheres validated the presence of mature LBs and their precursor organelles, 
multivesiculated bodies (MVB) (Fig. 2.2H). To perform an unbiased assessment of the 
identity of ABCA3:GFP expressing cells, we performed bulk RNA sequencing of sorted 
ABCA3:GFP+ vs. GFP- cells on day 31 of differentiation (n=3; Fig 2.2B, I, J). 888 genes 
were differentially upregulated in ABCA3GFP+ cells (FDR<0.01). Further analysis of 
the top 50 upregulated transcripts in the GFP+ population revealed enrichment of genes 
associated with LB and LB precursor organelles (Enrichr GO: cellular compartment 
analysis) (Fig 2.2L). Amongst the top 50 upregulated genes were AEC2 genes including 
ABCA3, SFTPB, SFTPA2, ADGRF5 (GPR116), NAPSA, SLC34A2, LAMP3, CTSH, 
and LPCAT1. ABCA3 was the number one most upregulated gene further supporting the 




alveolar epithelial genes (NKX2-1, ABCA3, SFTPC, LAMP3, LPCAT1) in 
ABCA3:GFP+ cells by RT-qPCR and found their expression levels were at or above the 










 Transcriptomic analysis also revealed SLC34A2, a sodium phosphate transporter, 
as a candidate surrogate cell surface marker expressed in ABCA3+ cells, consistent with 
recent findings from Korogi et al (2019). We prepared day 28 cells from triplicate 
differentiations of the BU3 AG line and found that sorting cells stained with anti-
SLC34A2 antibody resulted in enrichment of iAEC2s with >90% of SLC34A2 high cells 
expressing the ABCA3:GFP reporter. Moreover, SLC34A2 sorting resulted in the 
enrichment of cells expressing SLC34A2, ABCA3, SFTPC, NAPSA, and PGC 
transcripts, compared to pre-sort, mixed populations (Fig 2.3). Taken together, these 
results further support SLC34A2 as an effective surrogate marker that can be used to 





iAEC2s derived from ABCA3:GFP/SFTPCtdTomato bi-fluorescent reporter line allows 
the study of alveolar epithelial cell developmental kinetics 
 SFTPC message is expressed in the developing human distal lung tip by week 15 
of gestation 126 while ABCA3 protein expression has been described as first detectable at 




see if our reporters would recapitulate the temporal differences of SFTPC and ABCA3 
expression observed in vivo, we generated a new human ESC line bi-fluorescently 
targeted with the SFTPCtdTomato and ABCA3:GFP reporter (hereafter referred to as 
RUES2 STAG), enabling head-to-head comparison of each reporter’s expression in the 
same differentiation. To document the emergence and frequency of expression of each 
reporter, we harvested distal differentiations of RUES2 STAG from day 15 to day 66 for 
flow cytometry (Fig 2.4 C). On day 19, we first observed the emergence of 
SFTPCtdTomato+ cells followed by emergence of ABCA3:GFP on day 22 (Fig 2.4 A, B), 
consistent with the known delayed expression of ABCA3 compared to SFTPC in in vivo 
human lung development. The frequency of SFTPCtdTomato reporter expression remained 
relatively stable throughout the differentiation (8.02% ± 0.78% on day 22 to 10.55% ± 
1.22% on day 66 of the total cell population). In contrast, the frequency of ABCA3:GFP 
expressing cells increased with time, overtaking the tdTomato+ frequency and peaking on 
day 31 at  28.57% ± 7.3% (compared to the frequency of SFTPCtdTomato+ cells at this time 
point of 9.31% ± 3.34%; Fig 2.4A). The increased frequency of ABCA3:GFP expressing 
iAEC2s are consistent with our initial scRNA-seq data indicating ABCA3 message in the 
NKX2-1GFP single positive population (Fig 2.1 D), highlighting the capability of the 
ABCA3:GFP reporter to identify a potentially larger population of putative iAEC2s 









iAEC2 heterogeneity is supported by transcriptomic comparisons between 
ABCA3:GFP/SFTPCtdTomato reporter double positive and ABCA3:GFP single positive 
iAEC2s  
 Within the lung, SFTPC and ABCA3 are both expressed in mature AEC2s where 
their protein products can be found in lamellar bodies. In our differentiations using the bi-
fluorescent reporter line, we found that after day 22 of differentiation, almost all 
SFTPCtdTomato+ cells co-expressed ABCA3:GFP+ (Fig 2.4 B,D). Expression of the two 
reporters identified three distinct populations: ABCA3:GFP/SFTPCtdTomato double positive 
(DP), ABCA3:GFP single positive (SP), and reporter double negative populations (DN, 
Fig  2.4C,D). Bulk RNA sequencing of each of these three populations, purified by cell 
sorting (day 36; n=3 replicates), revealed 4023 differentially expressed genes in a pairwise 
comparison between reporter positive and reporter double negative populations (DEG, 
FDR<0.05, abs log2FC>1, Fig. 2.4E) with enrichment of the AEC2 program in both 
ABCA3:GFP single positive and ABCA3:GFP/SFTPCtdTomato double positive populations 
compared to double negative cells (see Fig 2.4E SFTPC, ADGRF5, SLC34A2, CTSH, 
NAPSA, SFTA2, and ABCA3). In contrast, the reporter double negative population was 
enriched in non-lung endodermal genes such as CDX2, CDH17, VIL1, TFF1, and AFP, 
consistent with our prior reports of some degree of instability or plasticity in iPSC-derived 
“lung” cells over time after sorting cells at early stages of lung directed differentiation 
98,124,129. 
 We next compared the ABCA3:GFP/SFTPCtdTomato double positive and 




we found high transcriptomic similarities with only 130 DEGs (abs log2FC>1, 
FDR<0.05). As expected, SFTPC was the number one most upregulated gene in the 
reporter double positive population, but was detectably expressed in both DP and SP 
populations (Fig 2.4F, I). Amongst the differentially upregulated genes in DP cells were 
surfactant-related genes such as SFTPC, NAPSA, and SFTPB while markers of distal 
lung epithelial progenitors, SOX9, TM4SF1 and markers of cell proliferation such as 
TOP2A, MKI67 were differentially upregulated in the ABCA3:GFP single positive 
population (Fig 2.4F, G). RT-qPCR expression assays measuring key AEC2 genes 
revealed the same NKX2-1 levels between the two reporter positive populations but 
slightly higher expression levels of ABCA3 and other key AEC2 surfactant-related genes 
such as SFTPC, NAPSA, LPCAT1 in the ABCA3:GFP/SFTPCtdTomato reporter double 
positive population (Fig 2.4I). Gene set enrichment analysis (GSEA) revealed 
upregulation in DP cells of pathways associated with surfactant lipid processing in 
AEC2s 97,130,131. For example, lipid metabolism and recycling pathways represented 4 out 
of the top 5 pathways including fatty acid metabolism, cholesterol homeostasis, 
adipogenesis, and peroxisome pathways (FDR<0.05, Fig 2.4J). In contrast, in the single 
positive ABCA3:GFP population, proliferation-related pathways were enriched, such as 
mitotic spindle, G2M checkpoints, E2F targets, hedgehog signaling, and KRAS 
signaling, (FDR≤0.001), suggestive of a more proliferative subset of iAEC2s. Taken 
together, these results, similar to our scRNA-Seq data (Fig 2.1) further supports 




definable by an inverse relationship between proliferation genes and surfactant or 
maturation related genes, including SFTPC. 
ABCA3:GFP single positive population is a more clonogenic and proliferative subset 
of iAEC2s  
 An emerging literature has suggested heterogeneity in AEC2s in vivo in mouse 
lungs, either during fetal lung development, adult homeostasis, or adult lung injury. For 
example, a distinct subset of AEC2s in vivo was recently reported and defined based on 
proliferative/progenitor potential, the cell surface marker, Tm4sf1, or high Wnt signaling 
levels 120-122. Hence, we profiled these same characteristics in our DP vs SP iAEC2 
populations, quantifying expression levels of Wnt signaling targets, AXIN2, LEF1, and 
NKD1, as well as TM4SF1, finding slight enrichment in SP cells (Fig 2.4H). GSEA 
analysis also revealed Wnt/Beta Catenin signaling to be enriched in SP cells, consistent 
with publications from our group97 and others 120,122 that Wnt signaling is higher in AEC2 
progenitors and downregulation of Wnt signaling promotes the maturation of primary and 
iPSC-derived AEC2s.  
 Because our results suggested SP iAEC2s may be a more progenitor-like, 
proliferative population than DP cells, we performed a series of functional studies to test 
this possibility. First, we performed EdU incorporation assays to formally quantify 
proliferation in each iPSC-derived population (Fig 2.5A). We found that 40.13% ± 6.64% 
of ABCA3:GFP single positive cells stained EdU positive while the 
SFTPCtdTomato/ABCA3:GFP double positive population had significantly lower EdU 




 Next, to see whether measurable differences in proliferation translated to 
functional differences in epithelial sphere outgrowth or clonogenicity, we measured 
colony forming efficiencies from single cell suspensions prepared from enzymatically 
digested spheres that first underwent sorting on day 29 to purify double reporter positive, 
single ABCA3:GFP positive and reporter double negative populations. We have 
previously published that epithelial sphere outgrowth in these conditions is clonal, arising 
from the proliferation of single cells 98.  After 12 days of clonal outgrowth, we found a 
smaller number of colonies (62± 2.83) arose from the double positive sorted outgrowth 
compared to the ABCA3:GFP single positive sorted outgrowth (77.33 ± 5.13) (Fig 2.5D, 
E). Moreover, measurements of colony size revealed larger colony diameter in the 
ABCA3:GFP single positive sorted outgrowth compared to the outgrowth from the 
reporter double positive population (Fig 2.5F), further suggesting increased proliferation 
and clonogenicity of SP compared to DP iAEC2s. These results were consistent with 
fluorescence imaging of a mixed population of iAEC2s expressing both populations in 
which the dual reporter positive spheres were smaller compared to the single 






SFTPCtdTomato/ABCA3:GFP double positive and ABCA3:GFP single positive iAEC2s 
can repopulate each other and are capable of surfactant processing 
 Given the higher levels of transcripts and enrichment of pathways associated with 
surfactant metabolism in the DP populations (Fig 2.4), we first considered the possibility 
that the SP population was a more proliferative, progenitor-like cell type, limited in its 
ability to process surfactant proteins, a hallmark function of mature AEC2s, compared to 
the DP population. To assess this possibility, we sorted pure populations of day 186 DP, 
SP, and DN populations and tested their ability to process surfactant precursor proteins 
(proSFTPB and proSFTPC) compared to sorted day 15 NKX2-1+ lung epithelial 
progenitor. In vivo, proSFTPB is processed from its 42kDa precursor protein to its 8kDa 




AEC2s 132. Western blot analysis of the sorted samples using an antibody specific to 
processed proSFTPB intermediates, including the final 8kDa mature peptide 133, revealed 
that while the DN sorted cells and the day 15 lung epithelial progenitor cells expectedly 
expressed little to no levels of the mature 8kDa SFTPB protein, both the DP and SP 
sorted cells were able to process high levels of mature SFTPB, albeit a slightly higher 
level in the DP sorted cells (Fig 2.6 A, B). Next, similar analysis using antibodies specific 
to proSFTPC to detect processing of the 21kDa precursor peptide through 16kDa and 6-
10kDa proSFTPC intermediates 134 confirmed 6-10kDa proSFTPC processing in both DP 
and SP population but none in DN or day 15 control, with slightly higher level of 
processed proSFTPC in the DP compared to the SP population (Fig 2.6 A, B). Combined, 
these data indicate both the DP and SP cells can functionally process surfactant proteins 
with slightly higher levels of processed SFTPB and SFTPC in the DP population 
consistent with higher levels of SFTPC and surfactant related genes by previous 









 Since both the DP and SP populations appeared to have surfactant processing 
function, we next considered the possibility that SP and DP cells represented 
interchangeable states of iAEC2s rather than distinct populations of immature 
developmental precursors and more mature progeny. To determine whether each sorted 
population would retain their original reporter expression or re-populate other 
populations, day 44 spheres were sorted into pure SFTPCtdTomato/ABCA3:GFP double 
positive, ABCA3:GFP single positive populations for re-plating and outgrowth (Fig 
2.6C). After 18 days of outgrowth (Fig 2.6 D, E), the double positive sorted cells had 
retained dual-reporter expression in 50.6% ± 11.23% of the cells. From the same 
outgrowth, single ABCA3:GFP positive population also emerged, making up a fraction 
(18.27% ± 3.73%) of the overall population. In the outgrowth from ABCA3:GFP SP 
sorted cells, we found retention of the original SP population phenotype in a subset of 
cells (35.67% ± 3.78% of the overall population) and an emergence of the 
SFTPCtdTomato/ABCA3:GFP double positive population in 6.29% ± 0.65% of the 
population. Notably, while the mean fluorescence intensity of the ABCA3:GFP+ 
populations did not change between the two sorted outgrowths, the mean tdTomato signal 
was significantly lower in the ABCA3:GFP single positive sorted population, suggestive 
of either lower SFTPC locus activity or recent activation of the locus (Fig 2.6 D, E, G). 
Taken together, these data demonstrate the propensity for each sorted population to self-
renew, maintaining the DP or SP phenotype of the parent population, but also some 




 Notably, in the reporter sorted outgrowths, we also observed a loss of all reporter 
expression in 27.73% ± 15.18% and 54.6% ± 3.65% of the sorted outgrowths of double 
positive and ABCA3:GFP single positive cells, respectively, consistent with either 
instability in some iPSC-derived “lung” cells over time 124,129 or reversion of cells to a 
less mature lung progenitor phenotype lacking in AEC2 gene expression. Regardless, 
these trends suggest that more mature cells (identified by DP reporter expression) are 
more stable in culture in terms of their iAEC2 phenotype than SP cells which appear 
more prone to lose their AEC2-specific reporter expression. 
 To formally test whether double negative cells represented some degree of 
reversion to immature lung progenitors that might be identifiable as NKX2-1+/ABCA3-
/SFTPC- cells, we evaluated whether the ABCA3:GFP reporter alone can capture the 
entirely of the NKX2-1+ lung epithelial population in our in vitro distal lung 
differentiation. Day 30 BU3AG spheres containing a mixed population of ABCA3:GFP+ 
and ABCA3:GFP negative cells were stained with CPM, a surrogate marker for NKX2-1 
previously described by Gotoh et al  (2014) 135. We found that while ABCA3:GFP+ 
iAEC2s encompassed 19.97% ± 6.07% of total CPM+ population, a subset of CPM 
positive cells (37.87% ± 0.75%) did not express ABCA3:GFP (Fig 2.6H). Validation of 
each sorted population by NKX2-1 intracellular staining (Fig 2.6H i-iii) confirmed 
positive NKX2-1 staining in the ABCA3:GFP/CPM double positive and CPM single 
positive populations and negative NKX2-1 staining for the ABAC3:GFP/CPM double 
negative population. These data provide evidence for the existence of a subset of NKX2-




co-staining of previously day 43 GFP-sorted day 151 BU3 AG cells with antibody 
against SLC34A2, a surrogate surface marker for AEC2s described previously by Korogi 
et al (2019) and found to be enriched in ABCA3:GFP+ iAEC2s by us (Fig 2.3), revealed 
a SLC34A2/ABCA3:GFP double negative population in addition to 58.3% SLC34A2 
positive and  33.2% ABCA3:GFP positive populations (Fig 2.6I), suggestive of a cell 
population previously expressing an AEC2 program that lost it passages later. 
Level of SFTPC mRNA expression in ABCA3:GFP+ iAEC2s identifies increasingly 
mature iAEC2s 
 We speculated that a variety of distal lung fates of varying maturation states 
might explain the various subsets of iPSC-derived cells present in passaged spheres, even 
after prolonged serial passaging of cells previously sorted on iAEC2 markers. Hence, to 
further delineate the heterogeneity of all cells in our distal lung differentiation, including 
AEC2 reporter “double negative” cells, we performed a scRNA-seq experiment using the 
10X Genomics platform on day 203 RUES2-STAG cells previously sorted two passages 
prior on ABCA3:GFP/SFTPCtdTomato double positivity (Fig 2.7A). To ensure equal 
representation of all observed cell populations, we sorted the same number of cells from 
each recognizable cell population including a SFTPCtdTomato/ABCA3:GFP double positive 
population (DP), ABCA3:GFP single positive population (GFP-SP), SFTPCtdTomato single 
positive population (Tdt-SP), and a reporter double negative population (DN, Fig 2.7B). 
In total, 3,654 cells were subjected to scRNA-seq analysis using Louvain clustering 
revealing 4 distinct clusters (res 0.1) in which cluster 2 was represented predominantly by 




sorted cells, cluster 1 was made up of the DN and SFTPCtdtomato SP populations, and 
cluster 4 was made up of a mixed population (Fig 2.7 C, D). Based on expression of 
canonical lung markers, DEG, and benchmark gene signatures from primary developing 
lung bud tip progenitors described in Nikolic et al (2017) 136, and primary human fetal 
and adult AEC2s described in Hurley et al. (2020), we annotated cluster 1 as “Distal bud 
tip-like”, cluster 2 as “iAEC2s”, cluster 3 as “immature iAEC2s”, and cluster 4 as 









Consistent with day 36 bulk RNA-seq data (Fig 2.4), ABCA3:GFP reporter expression 
was mostly restricted to the iAEC2 clusters (cluster 2 and 3), encompassing all cells 
expressing canonical AEC2 markers including ABCA3, SFTPB, SLC34A2, NAPSA, 
CTSH, SLPI, SFTPA2, PGC (Fig 2.7D). We found ABCA3 mRNA expression to not 
overlap perfectly with EGFP mRNA potentially due to 3' bias of the sequencing 
technique, resulting in higher read sensitivity for EGFP on the 3' end of the mRNA 
encoding ABCA3:GFP fusion protein. Notably, cells expressing SLC34A2 mRNA 
appeared to reliably capture the majority of cells in the iAEC2 clusters, comparable to the 
ABCA3:GFP reporter (Fig 2.2J) and consistent with the enrichment of AEC2 transcripts 
in RT-qPCR validation of SLC34A2 sorted iAEC2s (Fig 2.3), further supporting the 
utility of SLC34A2 as a surrogate marker for iAEC2s as previously described by Korogi 
et al. (2019).  
 Consistent with previous analysis (Fig 2.4), tdTomato reporter transcript 
expression did not capture all cells expressing SFTPC message (Fig 2.7 D, E). Moreover, 
tdTomato and SFTPC transcripts were not expressed in a majority of GFP-SP sorted cells 
(Fig 2.7 D, E). We found both tdTomato and SFTPC transcripts to be expressed in the 
distal bud tip-like and iAEC2s clusters reminiscent with the pattern of in vivo SFTPC 
expression in distal bud tip progenitors 126 and in mature AEC2s, respectively. Also 
consistent with previous bulk RNA-seq data (Fig 2.4), we saw similar transcripts levels 
between DP and GFP-SP sorted cells associated with AEC2 identity and surfactant 
processing, including SLPI, SFTPA1, CTSH, SFTPB, and SLC34A2 (Fig 2.7F) with the 




population. Unlike our day 36 analysis, however, we did not find clear proliferative 
differences between the DP and GFP-SP population (data not shown). 
 Notably, contrary to day 36 DN cells enriched in non-lung endodermal genes (Fig 
2.4), day 203 DN cells retained lung epithelial identity indicated by expression of NKX2-
1,  findings that are consistent with time dependent stabilization of distal lung fate as we 
have recently published124. Moreover, along with the Tdt-SP sorted population, which 
together with DN sorted cells, formed cluster 1, we found both the Tdt-SP and DN cells 
to enrich for ID2, and SOX9, associated with distal bud tip progenitors, as well as 
HMGA2, a marker of lung epithelial progenitor identity 137,138 (Fig 2.7G) and a loss of 
AEC2 gene expression compared to its parent population two passages prior of 100% DP 
sorted iAEC2s. 	
AEC2 heterogeneity in fetal and adult lung in vivo  
 Based on our data demonstrating a heterogeneous population of iAEC2s 
characterized by an inverse relationship between maturation and proliferation and 
highlighted by a gradient of SFTPC high to SFTPC low-expressing cells, we 
contemplated whether these heterogeneous subsets of AEC2s exist in nature either during 
embryological lung development or in adult lung. To do so, we re-analyzed available 
single cell RNA-seq datasets of E17.5 mouse developmental lung 123 and healthy adult 
human lungs 139,140.  
 From the E17.5 mouse data set containing all NKX2-1+ epithelial cells, we first 
identified two cell clusters described in Frank et al. (2019) as AEC2 (481 cells) and 




Direct comparison of the two AEC2 clusters revealed 512 differentially expressed genes 
(FDR<0.05) and higher expression levels of canonical AEC2 transcripts in the AEC2 
cluster compared to its precursor cells including Sftpc, the number 12 most upregulated 
gene, as well as Ctsh, Sftpb, Napsa, Lamp3, Slc34a2, and Abca3 (Fig 2.8 C,D). In 
contrast, the precursor cells expressed higher levels of Id2 and Sox9, transcripts 
associated with AEC2 progenitors (Fig 2.8 C,D). These findings were consistent with the 
trend observed in reporter DP and SP hPSC-derived AEC2 populations described above 
(fig 2.4-5) with the DP population expressing higher levels of canonical AEC2 transcripts 
including SFTPC and ABCA3. Further analysis of the top 70 upregulated transcripts in 
the AEC2 cluster (FDR<0.05) revealed gene enrichment associated with LB and LB 
precursor organelles (Enrichr GO: cellular compartment analysis, Fig S2.8 E) and 
pathways associated with surfactant homeostasis and phosphatidylcholine acyl-chain 
remodeling (Enrichr GO: Biological process), suggestive of a cellular trajectory towards 
maturing AEC2s and surfactant synthesis. In contrast, the top 70 upregulated transcripts 
in the AEC2 precursor cluster (FDR<0.05) enriched in genes regulated by the MYC 
(Enrichr: TRANSFAC and JASPAR PWMs, Fig 2.8 E) and pathways associated with 
increased cellular metabolism and anabolism such as mRNA processing, glycolysis, 
gluconeogenesis, cytoplasmic ribosomal proteins, and growth factor signaling pathways 
(Enrichr: WikiPathways mouse). Combined with lower expression levels of canonical 
AEC2 genes, including Sftpc, these enriched pathways are suggestive of a 






 We next re-analyzed two recent scRNA-seq datasets on adult healthy donor and 
diseased human lungs 139,140 by comparing SFTPC transcript levels in AEC2s of each 
group. Diseased lungs in the Habermann et al. study were composed of fibrotic lungs with 




A). Diseased lungs in the Reyfman et al. study were consistent with the clinical diagnosis 
of pulmonary fibrosis as a result of idiopathic pulmonary fibrosis (IPF), hypersensitivity 
pneumonitis (HP), polymyositis (PM), or systemic sclerosis (SSc, Fig 2.9 B). We found a 
more homogenous distribution of SFTPC expression in normal healthy quiescent human 
lungs at the individual level. However, we noticed a greater heterogeneity in SFTPC levels 
amongst diseased lungs (Fig 2.9 A, B), highlighting the possibility that a heterogeneous 
population of SFTPC low AEC2s may arise during lung injury.  
 
Discussion 
 Our results provide a thorough characterization of human PSC-derived distal lung 
epithelium using fluorescent knock-in reporters for canonical lung and AEC2 markers 
NKX2-1, SFTPC, and ABCA3. Through expression of combinations of these fluorescent 
reporters across two PSC lines and bulk RNA sequencing accompanied by functional and 
surfactant processing studies, we demonstrate iAEC2s to exist in interchanging and 
heterogeneous populations largely explained by their proliferative potential and 




 Consistent with our lab's previous findings, we find the SFTPCtdTomato reporter to 
be a reliable reporter to identify and isolate iAEC2s from our distal lung differentiation 
protocol 97,98,124. However, the TdTomato reporter appears to selectively identify only the 
cells expressing the highest levels of SFTPC message resulting in decreased iAEC2 
sensitivity (Fig 2.4, 2.7) and may also at times label non-AEC2 distal bud tip-like cells 
(Fig 2.7). We demonstrate that targeting another canonical AEC2 locus ABCA3 with a 
GFP fusion reporter enabled the identification of the majority of AEC2-like cells 
including those missed by SFTPCtdTomato, evidenced by the higher frequency of 
ABCA3:GFP expressing cells in a bi-fluorescent targeted line (Fig 2.4). Together with 
transcriptomic signatures enriched in canonical AEC2 transcripts in GFP+ cells (Fig 2.2, 
2.3), and functional processing of proSFTPB and proSFTPC surfactant proteins (Fig 2.6), 
we find ABCA3:GFP+ cells to be worthy of the name "iAEC2s" despite having lower 
levels of select AEC2 transcripts including SFTPC. 
 In our distal differentiation, we similarly discover the emergence of non-lung 
endodermal lineages consistent with phenotypic drift and possible forced expression of 
NKX2-1 in non-lung domains described in Hurley et al. (2020). Retention of the lung 
program is achieved following SFTPCtdTomato/ABCA3:GFP DP reporter sorting and 
repeated passaging, indicative of stabilization of lung epithelial identity. However, we 
found AEC2 reporter expression to fluctuate, with pure, reporter sorted populations 
losing their reporter expression to a more progenitor-like NKX2-1+ epithelium, enriched 
in SOX9 and ID2, associated with distal bud tip cells, suggestive of de-differentiation of 




development or periodically in healthy or diseased lung, these findings may simply be 
due to cellular plasticity arising from iPSC-derive lung cells and highlight the need to 
better characterize the epigenetic changes associated with AEC2 identity in our in vitro 
culture. 
 An important question to consider for the two AEC2-specific reporter positive 
populations (DP, SP) described in this study is whether they truly are different functional 
subpopulations of iAEC2s as opposed to different proliferative states of the same cell 
type. Contrary to this notion, our data indicate that when sorted on either the DP or SP 
positivity, both populations maintained significant proliferative populations without a 
change in their DP or SP reporter expression status (Fig 2.5), making the idea that these 
cells are purely defined by proliferative states unlikely. 
 Presence of a distinct, more proliferative and WNT-responsive alveolar 
progenitor-like cell has previously been described in the context of a homeostatic and 
injured adult mouse lung 120-122. So far, the presence of similar cell type in human in 
available human dataset published by Reyfman et al. (2019) found no such cell types in 
normal and fibrotic adult human lungs140. To assess whether the ABCA3:GFP SP 
iAEC2s would represent more WNT-responsive progenitor like cells as described in 
mice, we compared DP and SP populations revealing enrichment of TM4SF1 in the SP 
cells, a marker of mouse alveolar epithelial progenitors described in Zacharias et al. 
(2018). However, when looking at the relevant WNT pathway transcripts, we did not find 
differences in the transcript levels of AXIN2 or LEF1 with a slight but significant 




increased WNT signaling. While a healthy quiescent lung may have an over-
representation of a more homogeneous population of AEC2s, it remains possible that 
during lung injury or in vivo lung development that certain alveolar progenitor cells gain 
functional, proliferative advantages critical for lung regeneration or development. 
Therefore, iAEC2 heterogeneity observed in our in vitro model is perhaps an 
amplification of such existing heterogeneous AEC2 populations in vivo. 
 In our study, we observe a significant difference between the DP and SP cells in 
the expression of SFTPCtdTomato reporter as well as in SFTPC mRNA levels (Fig 2.4). To 
investigate whether the SFTPC low cells existed in vivo, we re-analyzed available in vivo 
datasets of developmental and adult lungs, finding Sftpc low cells expressing lower levels 
of AEC2 genes in E17.5 mouse described in Frank et al. (2019) akin to the SP cells in our 
human in vitro model. Re-analyses of existing adult human lung scRNA-seq datasets 
139,140 revealed no significant differences in SFTPC expression in healthy adult donor 
lungs beyond individual sample differences but more heterogeneous populations of 
AEC2s, identified by variable SFTPC expression, appeared in diseased lungs (Fig 2.9), 
suggestive that a greater level of AEC2 heterogeneity may occur in the context of lung 
injury and repair. A potential pit fall of these studies may be that they rely on SFTPC as a 
marker for AEC2 either to trace cells that once expressed SFTPC locus or to define 
AEC2s, possibly missing vital biology of otherwise functional AEC2 or its progenitors 
that never or only transiently expressed SFTPC message, diminishing our understanding 




 Taken together, in identifying a distinct population of iAEC2s in our human in 
vitro culture facilitated by our novel fusion reporter, our study highlights the importance 
of not solely relying on SFTPC but rather a broad spectrum of AEC2 markers to study the 
potentially heterogeneous population of AEC2s. Moreover, in combination with our 
iAEC2 model, the visualization of intracellular lamellar bodies highlighted by our 
ABCA3:GFP fusion reporter system is likely to aid in the study of various pulmonary 
diseases including those that affect lamellar body morphology such as the childhood 







CHAPTER 2: DISEASE MODELING OF CHILDHOOD INTERSTITIAL LUNG 
DISEASE CAUSED BY ABCA3 MUTATIONS USING PATIENT IPSC-DERIVED 
IAEC2 
 Previous use of cell line models is limited by the lack of relevant endogenous 
gene- and protein- level control as well as lack of relevant AEC2 physiology such as 
surfactant storage and production. A biologically relevant model that recapitulates 
primary AEC2 physiology will enable, for the first time, discovery of mutant-specific 
disease mechanisms and a powerful platform for the discovery of drugs to treat chILD 
caused by ABCA3 mutations.  
Rationale 
 Childhood interstitial lung disease (chILD) is a heterogenous group of genetic 
lung diseases affecting infants and children presenting with a range of symptoms such as 
respiratory distress at birth and shortness of breath 2,13,68,141. While many causal genes 
have been identified for chILD11,44,47,48, the most common are autosomal recessive 
mutations in the gene encoding ATP Binding Cassette A3 (ABCA3) protein 2,21, a 
lamellar body (LB)-associated lipid transporter exclusively expressed in the lung within 
the alveolar type II epithelial cells (AEC2) 66,128,142. Bronchoalveolar lavage samples from 
patients harboring ABCA3 mutations have decreased levels of pulmonary surfactant 29, a 
mixture of approximately 90% phospholipids and 10% proteins secreted by the AEC2s 
28,35 that functions by reducing surface tension in alveoli. Although surfactant deficiency 
resulting from the loss of ABCA3 lipid transporting function is widely considered to be a 




have temporary to no improvement in their respiratory symptoms 55,143,144, highlighting 
the lack of understanding on how ABCA3 mutations instigate this disease beyond 
conventional surfactant deficiency, starting from its effects on AEC2s.  
 To date, obtaining rare, ABCA3 mutant primary human AEC2s as well as 
difficulties in culturing primary AEC2s, in general, have posed major hurdles in studying 
the over 250 identified ABCA3 mutations 15,55 in the relevant cell type, with studies 
relying instead on genetically-engineered ABCA3 overexpression in cancer or 
immortalized cells 75,78,145. These studies using heterologous cell lines, have classified 
ABCA3 mutations into two broad subtypes: type I mutations resulting in mistrafficking 
of the mutant ABCA3 protein, or type II mutations resulting in decreased enzymatic 
function 75,78,145. These cell line models, however, do not recapitulate key AEC2 
physiology such as surfactant secretion or ABCA3 expression under endogenous gene 
regulation, undermining the biological relevance of these findings. Encouragingly, the 
ability to derive induced pluripotent stem cells (iPSCs) from patients, advances in gene-
editing technologies, and significant progress in the directed differentiation of iPSCs to 
cells that transcriptionally and functionally resemble primary AEC2s (iAEC2s)97,98 have 
recently enabled human AEC2 disease modeling, recapitulating dysmorphic LB 
phenotypes caused by SFTPB mutations, another cause of chILD, using the patient's own 
cells 97.  
 In the present study, we apply these techniques to study the downstream effects of 
ABCA3 mutations in patient iPSC-derived iAEC2s. Because most patients carry 




homozygous ABCA3 mutations in patients with documented chILD clinical phenotypes. 
We found two such patients, a homozygous W308R ABCA3 mutant and a homozygous 
E690K mutant and generated their corresponding iPSC lines. Through in silico models, 
the W308R mutation is predicted to cause significant ABCA3 mistrafficking due to the 
change from a hydrophobic to a polar amino acid residue localized to the transmembrane 
domain of the protein. From studies in a cell line model, the E690K mutation is predicted 
to result in dysfunctional ATP hydrolysis due to the mutation’s location in the protein’s 
nucleotide binding domain 146. By differentiating these ABCA3 patient iPSC-lines into 
iAEC2s, in parallel with their CRISPR/Cas9 gene-corrected syngeneic control lines, we 
find patient iPSC-derived iAEC2s recapitulate clinically observed surfactant deficiency 
through attenuated secretion of surfactant phospholipids. Using different human PSC 
lines containing knock-in ABCA3:GFP reporter CRISPR-mutagenized to express the 
corresponding ABCA3 mutations, we find both mutant ABCA3 proteins traffic normally 
but form smaller LBs. Finally, global transcriptomic analyses revealed diminished 
surfactant synthesis and upregulation of NFkB pathway activity in ABCA3 mutant 
iAEC2s shared across different genetic backgrounds, resulting in the secretion of pro-
inflammatory cytokines. 
Methods 
Patient iPSCs and reprogramming and maintenance 
 All human iPSCs were maintained in feeder free conditions and passaged as 
indicated in the method section in chapter 1. Reprogramming of skin fibroblasts from the 




cells from the patient with homozygous W308R ABCA3 mutation was done using Sendai 
virus Cytotune 2 Kit (Thermo Fisher). Picked candidate clones from each genotype were 
characterized for pluripotency by staining for pluripotency markers using monoclonal 
mouse antibodies against TRA1-81 and TRA 1-60 (Stem Cell Technologies, Catalog # 
60065AD.1, Catalog # 60064AD.1) and found to be karyotypically normal (Cell Line 
Genetics). Reprogramming of the BU3 human iPSC line was previously done in 
Kurmann et al. (2015) 147. 
Gene Editing of Human iPSC Lines 
 Generation of E690K and W308R ABCA3 mutant patient iPSC lines mono-allelic 
targeted with knock-in tdTomato reporter at the ATG of endogenous SFTPC locus was 
performed using TALENS gene editing tools follow the same methods detailed in Jacob 
et al. (2017).  
CRISPR-Cas9 based gene editing: 
 For bi-allelic, foot-print free ABCA3 gene correction of patient iPSC lines, 20bp 
guide RNA specific to the E690K mutation 5’-GATGGCGTCCATGCCCGAGG-3’ and 
W308R mutation 5’-GCTGGCTGCACTGGAGTGCCCGG-3’ were identified using an 
online guide RNA identifier (crispr.mit.edu) based on proximity to mutation site and 
fidelity scores and inserted using conventional cloning techniques into pSpCas9 plasmids 
148 containing sequences encoding the Cas9 protein, site-specific guide RNAs and 
constitutively expressed GFP. For homologous recombination after CRISPR Cas9-
induced double stranded break, 70 bp single stranded DNA oligonucleotides (ssODN) 




ACTGTGTCTCTCCCTCCAGGTGCTGATACTGGAC GAG CCG ACG TCA GGC 
ATG GAC GCC AT C TCCAGGAGG 3’) and the W308R mutation (5’ 
GGCGATGAGGAGGAAGAGGAAGAACAAGAGGAACCAAGCGCTCCAGTGCAG
CCAGCTGCTGAGCCCCATC 3’). Each donor ssODN contains silent mutations 
resulting in DNA sequences recognized restriction enzymes (AatII site for E690K, and 
AleI for W308R) upon successful homologous recombination, allowing for screening of 
iPSC clones with restriction digestion of PCR products. 
 iPSC nucleofection of CRISPR oligos and ssODNs were done using the P3 
Primary Cell 4D-Nucleofector X Kit (Lonza, cat no. V4XP-3024). 5X106 iPSCs were 
nucleofected with 5µg of pSpCas9 plasmid containing desired gRNA and 5µg of ssODN 
in 100 µl total volume of P3 nucleofection solution (Lonza) and re-plated on 4 wells of 
matrigel coated 6-well tissue culture dish (Corning) and fed with mTeSR media (Stem 
Cell Technologies) and RI, then re-fed with just mTeSR after 24 hours. 48 hours after 
nucleofection, GFP+ cells were sorted and plated at a density of 1,000-3,000 cells per 
well of a 6 well tissue culture plated pre-seeded with mouse embryonic fibroblast. After 
approximately 2 weeks, clonal outgrowths were harvested for genomic DNA for PCR 
amplification surrounding region of homologous recombination with primer pairs, F: 5’ 
AAGGGCCTGTCACGTCAGAA 3’, R: 5’ CTGATCTGAGGGCCCTTCATGAA 3’ for 
the E690K locus, and primer pairs, F: 5’ CAGGCGCTTTTGGTCAGTGAA 3’, R: 5’ 
CTACATTTGGCTTCACCTGCAGG 3’, for the W308R locus and screened using 
restriction enzyme digestion. Gene-correction of successfully digested clones was 




 For CRISPR Cas9 single nucleotide E690K and W308R mutagenesis of the 
wildtype BU3-AG iPSC line, the same guide RNAs used for gene-correction of patient 
iPSC lines were used in conjunction with new ssODN donors: 5' 
ACTGTGTCTCTCCCTCCAGGTGCTGATACTGGACAAGCCCACCTCGGGCATGG
ACGCCATCTCCAGGAGG 3' for E690K mutation, and 5’ 
GGCGATGAGGAGGAAGAGGAAGAACAAGAGGAACCGAGCGCTCCAGTGCAG
CCAGCTGCTGAGCCCCATC 3’ for W308R mutation containing mutated sequences. 
 For the L101P mutagenesis of BU3-AG iPSC line, guide RNA 5’ 
CGTCACTGAGACAGTGCGCAGGG 3’ and ssODN of 5’ 
TGTCTCACCTCGCATGTTGATCACAGGTGCTCTGCGCACTGTCTCAGTGACGG
TCTTGGCAGCGTCACTG 3’ was used, containing restriction digest sequence for 
BsiHKAI restriction enzyme for successful recombination screening. 
Directed Differentiation of iAEC2s 
 Reagents used and protocol detailing the directed differentiation of patient and 
CRISPR-mutagenized iPSC lines were a conducted as previously described in chapter 1 
(Directed Differentiation of Human PSCs to Distal Lung Epithelium).  
 To increase the frequencies of SFTPCtdTomato or ABCA3:GFP-expressing iAEC2s, 
CHIR withdrawal and addback distal lung progenitor cells were conducted first by 
plating day 30 CPM sorted cells in 3D matrigel and fed with CK+DCI and RI. After 48 
hours, cultured cells were re-fed KGF+ DCI and RI (KDCI+RI) "CHIR withdrawal" for 5 




2D Monolayer Culture of iAEC2s 
 2D monolayered iAEC2 culture were made by plating either day 15 
CD47hi/CD26lo sorted, NKX2-1 enriched distal lung epithelium or day 43+ single-cell 
suspension of trypsin-dissociated 3D epithelial spheres in matrigel coated 48-well tissue 
culture plate (Corning) at 300,000 to 600,000 cells per well. 2D cultures were fed with 
CK+DCI with RI every other day. 
Quantitative RT-qPCR 
qRT-PCR measuring expression levels of key AEC2 and non-lung endodermal genes 
comparing 2D vs 3D plated distal differentiations was performed as previously described 
in chapter 1 (Quantitative Reverse Transcriptase PCR). 
iAEC2 Secretagogue-induction and Lipidomic Analysis of Secreted Contents 
 For visualization of lipid secretion using day 75 BU-AG iAEC2s, day 72 iAEC2 
culture expressing ABCA3:GFP was single-cell cell dissociated and plated as a 2D 
monolayer on matrigel-coated coverslip-bottomed dish (MatTek, part no. P35G-1.5-14-
C) at 1X106  cells per well. iAEC2 secretion was induced using secretagogue cocktail 
consisting of final concentrations of 100nM ATP (Thermo Fisher cat no. R0441) and 
300nM Phorbol12-myristate 13-acetate (PMA, Cayman Chemicals, item no. 10008014). 
Visualization of secreted lipid contents was achieved by feeding cultured cells with 
5µg/mL of FM4-64 dye (Thermo Fisher, cat no. T13320) 20 min prior to induction with 




 For lipidomic analyses of patient iAEC2 supernatants, day 171-173 patient 
iAEC2s from triplicate differentiations (n=3) of separated at day 0 (for E690K vs cE690 
syngeneic pair) and separated at day 133 (for W308R vs cW308 syngeneic pair) were 
plated in 2D monolayer culture at 300,000 cells per well and fed with CK+DCI+RI for 14 
days. On day 185-187, cells were treated either with secretagogues cocktail or DMSO 
control for 24 hours followed by collection of cell pellets for DNA quantitation and 
culture supernatants for lipidomic analyses by mass spectrometry as detailed in Jacob et 
al. (2017). Total phosphatidylcholine (PC) composition and 32:0 PC (DPPC) composition 
is reported as "Absolute Quantitation" nmol/µg protein or nmol/µg DNA.  
Immunofluorescence Imaging 
 Routine live-cell fluorescent imaging was done as previously described in chapter 
1 using Keyence BZ-X800 microscope (Keyence, Japan). Live-cell confocal imaging of 
secretagogue-induced iAEC2 secretion and other 2D plated iAEC2s was conducted using 
reagents described above and LSM 880 Laser Scanning Confocal Microscope (Zeiss, 
Germany). 
Flow Cytometry and Cell sorting  
 Cell sorting protocols of day 15 NKX2-1+ lung epithelial progenitors by 
CD47hi/CD26lo, day 30 re-enrichment of NKX2-1 using monoclonal antibody against 
CPM, iAEC2 sorting by ABCA3:GFP or SFTPCtdTomato reporter expressions were 




Bulk RNA sequencing 
 The following samples were harvested in Qiazol (QIAGEN) for bulk RNA-
sequencing analysis: (1) day 43 SFTPCtdTomato+ E690K patient iAEC2 (2) day 43 
SFTPCtdTomato+ cE690 patient iAEC2 (3) day 44 SFTPCtdTomato+ W308R patient iAEC2s 
(4) day 44 SFTPCtdTomato+ cW308 patient iAEC2s (5) day 43 ABCA3:GFP+ wildtype 
BU3 iAEC2s (6) day 44 E690K ABCA3:GFP+ BU3 iAEC2s (7) day 44 W308R 
ABCA3:GFP+ BU3 iAEC2s. All lines were triplicate differentiations separated at day 0 
(n=3). Sequencing libraries were prepared from total RNA samples using Illumina 
TruSeq RNA Sample Preparation Kit v2. mRNA was isolated using magnetic beads-
based poly(A) selection, fragmented, and randomly fragmented for reverse transcription, 
followed by synthesis of cDNA fragments. cDNA fragments were then end-paired, and 
ligated to Illumina Paored-End sequencing adapters. The products were end-paired and 
PCR-amplified to creat the final cDNA library. Libraries from patient iAEC2s samples 
were pooled in groups of four and sequenced four per lane on the Illumina NextSeq 500 
to generate and average of 49 million paired-end reads per sample. The 3 libraries from 
BU3 iPSC-derived iAEC2s were pooled and sequenced four per lane and sequenced, 
generating an average of 53 million paired-end reads per sample.  
EdU Incorporation and Colony Forming Efficiency Assays 
 For colony formation efficiency (CFE) assays, triplicate differentiations (n=3, 
separated at day 0) of patient ABCA3 mutant or gene-corrected day 43 SFTPCtdTomato-
sorted iAEC2s were plated at 400 cells/µl in 25µl 3D matrigel droplet. Stitched, and full 




X800 Keyence microscope for CFE analyses reported as total number of colonies divided 
by input cell per droplet. For EdU incorporation assay of SFTPCtdTomato+ iAEC2s, the 
same cells used for CFE quantitation were inoculated on day 10 with 10µM EdU, as 
detailed in chapter 1, for 24 hours followed by cell sorting for SFTPCtdTomato+ 
iAEC2s. Sorted cells were fixed, permeabilized, and stained with the Click-iT reaction 
mixture (Invitrogen) according to the manufacturer’s protocol. The percentage of iAEC2s 
that incorporated EdU was determined by flow cytometry (Stratedigm, CA, USA). 
Measurement of NFkB Pathway Activity in Patient iAEC2s 
 Day 258 W308R and cW308 patient iAEC2s, and day 158 E690K and cE690 
iAEC2s grown in 3D culture were dissociated to single-cell suspension for lentiviral 
infection. 100,000 iAEC2s from each genotype infected with the lentivirus at 20 MOI 
and polybrene for 4 hours at 37 oC in 1.5ml tube and, plated in triplicate 3D matrigel 
droplets and re-fed with CK+DCI. 14 days after plating, 15,000 GFP+ infected cells and 
uninfected cells per genotype were added to 96-well microplates (Thermo Fisher cat. no. 
M33089) for luminescence measurements using Dual-Luciferase Reporter Assay Kit 
(Promega) according to manufacturer's recommendations and using Infinite 200 PRO 
microplate reader (TECAN, Switzerland). 
iAEC2 Supernatant Cytokine and Chemokine Measurements 
 Patient iAEC2 supernatants were collected from triplicate differentiations (all 
lines separated at day 0, n=3) of day 97 E690K and cE690 patient iAEC2s and day 100 




plating on matrigel coated 48-well plates. Supernatant protein concentrations of SP-D, 
M-CSF, IL-23, GM-CSF, CXCL5, CXCL1, CXCL17, CCL20, CCL11, CCL17, CCL22, 
CCL4, OPN, MMP1, MMP7, MMP10, MMP13, IL-8, IL-1beta, TNF-alpha, IL-11, IL-
13, IL-33, IL-6, IL-4, G-CSF, CXCL1, CXCL2, CX3CL1, CCL2, IFN-alpha, IFN-
gamma, IFN-beta, were measured by using human magnetic Luminex assay (R&D 
systems) on Bio-Plex 200 multiplexing analyzer system (Bio-Rad). 
Results 
E690K and W308R autosomal recessive ABCA3 mutations cause severe respiratory 
disease in newborns 
 Clinical records for our patients identified with E690K and W308R homozygous 
ABCA3 mutations described the rapid onset of neonatal respiratory symptoms which 
were refractory to all treatments. The patient with homozygous E690K ABCA3 mutation 
(c.2068G>A) was a female infant born at 36 weeks gestation. Further genetic analysis 
revealed her homozygous ABCA3 mutation to be the result of uniparental disomy of the 
maternal mutant allele. Within a few hours of birth, the patient developed symptoms of 
respiratory distress with chest radiographs revealing persistent bilateral pulmonary 
infiltrates (Fig 3.1A). An echocardiogram demonstrated tricuspid regurgitation and signs 
of pulmonary hypertension. Treatment for her respiratory symptoms with mechanical 
ventilation, supplemental oxygen, nitric oxide, steroids, and multiple doses of exogenous 
surfactant were ineffective, resulting in persistent respiratory failure. The patient received 
a bilateral lung transplant at 5 months of age. Explant histology demonstrated diffuse 




hyperplasia, extensive neutrophilic infiltrates of the airways and alveoli, chronic 
interstitial inflammation with lymphoid aggregates, and intimal thickening of small 
pulmonary arteries (Fig 3.1B). Electron microscopy of AEC2s demonstrated small, dense 
lamellar bodies and tightly wound, small lamellar structures (Fig 3.1C). Genetic 
evaluation found no mutations in other genes associated with surfactant production, such 
as SFTPC or SFTPB genes.  
 The patient identified with homozygous W308R ABCA3 mutation (c.922T>C) 
was a term female infant who developed progressive tachypnea, increased work of 
breathing, and respiratory failure requiring mechanical ventilation. A chest radiograph 
taken at 1 month of age demonstrated diffuse, severe, bilateral interstitial infiltrates, 
ground glass opacities and scattered small cystic areas (Fig 3.1D). Treatment with 
exogenous surfactant, supplemental oxygen, steroids, and hydroxychloroquine, did not 
result in clear improvement in lung function. Due to persistent respiratory failure and 
recurrent infections from to her underlying lung disease, at 21 months of age the patient 
underwent lung transplantation. Explant histology demonstrated extensive alveolar 
remodeling diffuse AEC2 hyperplasia, intra-alveolar macrophages, alveolar septal 





Derivation of E690K and W308R ABCA3 mutant and gene-corrected patient iAEC2s 
 Patient-derived iPSCs were generated from patient PMBCs (E690K) and from 
patient skin fibroblasts (W308R) using transgene-free Sendai virus 149,150 encoding 
OCT4, KLF4, SOX2, and MYC 83,151,152 (E690K-iPSC, W308R-iPSC, Fig 3.2 A,C). 
Pluripotency of final iPSC clones were confirmed by immunostaining using with human 
pluripotency marker TRA1-81 (Fig 3.2A) 153 and determined to have normal karyotypes. 
Both patient samples were received from Washington University School of Medicine in 
St. Louis. To isolate a pure population of diseased iAEC2s specific to each ABCA3 




editing tools described in Jacob et al. (2017) to target the tdTomato reporter mono-
allelically to the SFTPC locus of each ABCA3 mutant iPSC line. Because iPSC lines 
generated from distinct individuals are known to exhibit different differentiation 
efficiencies and phenotypes due to differences in genetic backgrounds, we generated 
syngeneic gene-corrected control iPSCs lines for each corresponding ABCA3 mutation. 
We used CRISPR/Cas9 gene editing to achieve footprint-free homologous recombination 
(cE690-iPSCs, cW308-iPSCs, Fig 3.2A-B) 148. For E690K gene correction, of the 61 
clones picked, 5 achieved homozygous correction and for the W308R gene correction, of 








 To determine whether each of the patient-specific iPSC lines were capable of 
differentiating into iAEC2s, we next conducted triplicate differentiations using our 
previously published distal lung differentiation protocol (Fig. 3.3 A) 97,98. On day 15 of 
directed differentiation, we found both patient and gene-corrected lines were able to 
generate NKX2-1+ lung epithelial progenitors quantified by expression of surrogate cell 
surface markers, CD47hi/CD26lo 109 (Fig 3.3B) shown previously to enrich for NKX2-1+ 
lung progenitors and later confirmed by flow cytometry analyses of intracellular staining 
for NKX2-1 (Fig 3.3C). Enrichment of NKX2-1+ lung progenitors by CD47hi/CD26lo 
cell sorting was followed by further differentiation into distal lung using the previously 
described distal differentiation media containing CHIR, KGF, dexamethasone, cycling 
AMP, and IBMX (CK+DCI media) 97. This resulted in expression of the SFTPCtdTomato 
reporter starting between day 18-21 in all 4 genotypes (Fig 3.3D). Because iPSC-derived 
cells can exhibit heterogeneity due to cellular plasticity by upregulating non-lung 
endodermal programs 124 and may de-differentiate (chapter 1), on day 29-30, we enriched 
for NKX2-1 again using cell sorting for surrogate marker CPM previously described by 
Gotoh et al., (2014, Fig 3.3F) 135 followed by withdrawal of CHIR, a WNT pathway 
stimulator, and then addback of  CHIR 5 days later, shown previously to improve 
frequency of SFTPCtdTomato+ iAEC2s by Jacob et al., (2017, 2019, Fig 3.3 A, E, G, H). 
Frequency of SFTPCtdTomato expression increased between day 30 and day 43 in E690K 
cells from 0.09%±0.01 to 33.47%±1.53, in cE690 cells from 0.38%±0.05 to 
30.53%±1.83, in W308R cells from 3.66%±0.81 to 28.63%±1.68, and in cW308 cells 










ABCA3 Mutant iAEC2s Have Attenuated Surfactant Lipid Secretion 
	 Clinically, defects in surfactant transport caused by bi-allelic ABCA3 mutations 
can result in surfactant deficiency, marked by decreased levels of surfactant phospholipid 
species such as phosphatidylcholine (PC) and dipalmitoyl phosphatidylcholine (DPPC, 
PC32:0) 29,67. To assess whether our iAEC2 disease model can recapitulate this 
phenotype, we sought to measure levels of surfactant phospholipids secreted by the 
iAEC2s generated from each line (Fig 3.3).  
 Because our distal lung cultures described previously in Jacob et al., (2017, 2019) 
are typically conducted in a 3D format in which iAEC2s making up the alveolospheres 
are oriented apically towards the sphere lumen, it is difficult to readily access apically 
secreted contents such as surfactant for measurement. To better access secreted contents 
by iAEC2s, we sought to develop a 2D iAEC2 monolayer culture system, simultaneously 
enabling easy access to secreted material and monitoring of cultured cells in real time by 
high-resolution imaging (Fig 3.4A). To see whether 2D monolayer cultured cells can 




the ABCA3 protein, we plated day 15 NKX2-1 enriched lung progenitor cells 
differentiated from the BU3 AG (ABCA3:GFP) iPSC reporter line (chapter 1), in 2D 
monolayer or 3D alveolosphere cultures (Fig 3.4B). The BU3 AG iPSC line contains a 
bi-allelic ABCA3:GFP knock-in fusion reporter, enabling readout of both ABCA3 
protein expression and iAEC2 identity. Starting around day 21, we found ABCA3:GFP 
reporter to be expressed in both 2D (Fig 3.4C) and 3D cultures. On day 34, the 2D 
cultured cells appeared to express higher frequency of ABCA3:GFP+ iAEC2s by 
fluorescent microscopy (Fig 3.4C).  Flow cytometry analysis of day 34 outgrowth from 
day 15 NKX2-1 enriched 2D  and 3D culture cells and NKX2-1 depleted 3D cultured 
cells (negative control) confirmed this observation with 2D and 3D cultured cells 
expressing ABCA3:GFP reporter in 33.27%±4.29 and 13.04%±3.43 of the total cell 
population, respectively. This constituted in a near 3-fold increase in the frequency of 
ABCA3:GFP+ cells grown in the 2D cultured condition while the NKX2-1 depleted 
outgrowth only expressed 1.67%±0.22 (Fig 3.4D). Consistent with these findings, qRT-
PCR of day 32 cells 2D cultured cells had higher expression levels of ABCA3 and 
NAPSA, another LB-associated gene, and depletion of non-lung endodermal markers 
AFP, CDX2, compared to 3D cultured cells (Fig 3.4E). Moreover, we observed higher 
expression of NKX2-1 in 2D cultured condition, suggesting increased ABCA3:GFP 
expression may partly be explained by retention of the NKX2-1+ lung program. 
Importantly, we observed that iAEC2s could be similarly transitioned from 3D to 2D 
cultures at multiple time points during iAEC2 epithelial sphere passaging (such as day 




indicate 2D monolayer-cultured cells retain their AEC2 programs and readily express 
ABCA3 protein. 
 Next, to determine whether 2D cultured iAEC2s are capable of surfactant lipid 
secretion, we plated day 75 ABCA3:GFP-expressing iAEC2s in our 2D culture condition 
and tested responses to treatment with secretagogues (ATP(100µM), Phorbol 12-
myristate 13-acetaten(300nM)). We monitored for potential secretagogue-induced LB 
exocytosis by culturing cells in a media containing FM4-64, a lipophilic dye, for live-cell 
confocal imaging. Within 15min of secretagogue addition, FM4-64 fluorescent signal 
arose from the GFP+ intracellular vesicles near the apical membrane of iAEC2s, whereas 
no signal was detected in the absence of secretagogues (Fig 3.4 F,G). These data 
demonstrate ABCA3:GFP+ iAEC2s to be capable of responding to secretagogue signals 













 To assess whether iAEC2s derived from our patient-specific iPSCs recapitulated 
the clinical phenotype of surfactant deficiency, we performed secretagogue-induced 
lipidomic analysis on patient and syngeneic gene-corrected iAEC2s plated in our 2D 
culture system (Fig 3.4H). Consistent with previously published clinical findings of 
decreased phosphatidylcholine (PC) measured in the bronchoalveolar lavage fluid 
samples of patients with recessive ABCA3 mutations, we observed attenuated secretion 
of overall PC species, including DPPC, in the W308R ABCA3 mutant iAEC2s (W308R, 
E690K) compared to their syngeneic gene-corrected control iAEC2s (cW308, cE690, Fig 
3.4H, I). Moreover, the attenuated PC secretion in the W308R mutant iAEC2s could not 
be rescued with the addition of secretagogues (W308R+sec) despite increased level of PC 
secretion after treatment in the gene-corrected control (cW308+sec). These results 
demonstrate functional restoration of ABCA3-dependent surfactant lipid transport by our 
gene editing technique as well as faithful recapitulation of the clinically observed 





iAEC2s Expressing E690K and W308R Mutant ABCA3 Proteins Contain Smaller 
Lamellar Bodies 
 We next sought to determine whether ABCA3 mutations are sufficient to result in 
either ABCA3 protein trafficking or altered LB size and function if expressed in iAEC2s 
of an independent genetic background. We thus used CRISPR/Cas9-mediated 
mutagenesis of the ABCA3 locus to introduce each ABCA3 mutation (E690K and 
W308R) into a normal BU3 AG iPSC line which we previously engineered to carry an 
ABCA3:GFP reporter (chapter 1). To see how our mutations of interest compare against 
a known, severe mistrafficking ABCA3 mutant (L101P) we also engineered a parallel 
BU3 line to carry this mutation. Thus, in total, we generated 4 parallel syngeneic BU3 
iPSC lines with either the normal ABCA3 coding sequence fused to the GFP reporter 
(ABCA:GFP) or 3 mutagenized versions of the endogenous locus engineered to express 
the  ABCA3:GFP fusion construct carrying the E690K, W308R,  or L101P mutation. To 
generate these 4 lines, we employed CRISPR/Cas9-based single nucleotide mutagenesis 
of the original BU3 AG iPSC line (Fig 3.5A) using the same guide RNAs previously used 
for gene-correction of patient iPSC lines (Fig 3.2). To also see how A549 cell line 
models, previously used to study ABCA3 biology, compare to our iAEC2 model, we also 
generated 4 A549 cell lines using lentiviral constructs encoding GFP fused to the 
wildtype, E690K, W308R, or L101P ABCA3 mutant coding sequences, with each 
lentiviral ABCA3:GFP fusion cassette driven by a constitutively and ubiquitously active 
EF1aL promoter, resulting in stable, forced-overexpression of these ABCA3 protein 








 We differentiated all 4 BU3 ABCA3:GFP iPSC lines to iAEC2s using our distal 
lung differentiation protocol (Fig 3.3A) and compared differentiation efficiencies into 
iAEC2s by FACS for the GFP reporter. We observed decreased frequency of 
ABCA3:GFP+ iAEC2s at day 43-44 across all three mutant lines compared to the 
syngeneic wildtype line (Fig 3.5 B). The wildtype, E690K, W308R, and L101P AG lines 
expressed GFP in 41.43%±1.58, 32.36%±0.95, 21.63%±0.52, and 10.66%±0.91 
respectively (Fig 3.5C). We also observed lower mean GFP fluorescence intensities in 
mutant iAEC2s (Fig 3.5D) indicating lower levels of ABCA3:GFP expression suggestive 
of possible iAEC2 dysfunction as a direct or indirect result of ABCA3 mutations or 
delayed iAEC2 differentiation. High resolution confocal imaging of intracellular wildtype 
and mutant ABCA3:GFP fusion proteins revealed the expected vesicular localization 
pattern of the wildtype ABCA3:GFP fusion proteins and mis-localization of L101P 
mutant protein (mistrafficking positive control) in a non-vesicular diffuse pattern, as 
expected, in both our iAEC2 (Fig 3.5E) and A549 cells (Fig 3.6B). Similar to the 
wildtype protein, both the E690K and W308R mutant proteins appeared to localize to 
intracellular vesicles in the iAEC2 and A549 cell models (Fig 3.5E; Fig 3.6C) contrary to 
the initial in silico prediction that the W308R mutation would result in mutant ABCA3 
protein mistrafficking. The vesicles outlined by mutant ABCA3 proteins, however, were 
significantly smaller in size compared to those outlined by wildtype proteins with average 
diameters of 0.72µm±0.04 for E690K mutant and 0.67µm±0.04 for the W308R mutant 
compared to 1.53µm±0.09 in wildtype vesicles (Fig 3.5E, F; Fig 3.6 C-D). These smaller 




(Fig 3.1C) and previously published findings 21 describing small lamellar bodies in 
patients with ABCA3 mutations. To confirm our initial confocal findings of seemingly 
undisrupted ABAC3 trafficking in both E690K and W308R mutant, we performed 
western blot analysis of ABCA3 protein proteolysis from a 220kDa to 180kDa product, 
indicative of successful post-Golgi ABCA3 trafficking. Consistent with our confocal 
observations, in both iAEC2 and A549 models, we found an absence of the 180kDa band 
in the L101P mutant but presence of the 180kDa band in the E690K and W308R mutant 









Transcriptomic Analyses of ABCA3 Mutant vs Gene-corrected iAEC2s Reveal 
Upregulations of Inflammatory Pathways  
 To better characterize disease-causing mechanisms using an unbiased approach, 
we performed bulk RNA sequencing on day 43-44 (n=3 per genotype, Fig 3.3G, 3.7A) of 
patient-specific SFTPCtdTomato-expressing iAEC2s (E690K and W308R mutants) and their 
gene-corrected syngeneic control iAEC2s as well as the one wildtype and three CRISPR-
mutagenized ABCA3:GFP+ iAEC2s (Fig 3.5B, 3.7A).  
 Pairwise comparisons between each paired pre- vs post- gene corrected patient 
specific iAEC2 sample revealed 1384 differentially expressed genes (DEG) for the 
E690K mutant and 254 genes for the W308R mutant (FDR<0.05, absolute log2FC>1). 
Amongst the top 50 genes enriched in the E690K iAEC2s were genes associated with 
TNFa_NFkB signaling such as TNFRSF10B, IL23A, and NFKB1, as well as other 
proinflammatory genes such as TGFb and protein chaperons such as HSPA1A. Notable 
top enriched genes in the W308R iAEC2s included known cell death regulators CFLAR, 
GPC3, toll like receptors TLR2, suggestive of a diseased cell. Analyses of all DEGs by 
gene set enrichment analysis (GSEA) using MSigDM hallmark gene sets 154 revealed 
inflammatory pathways enriched in the E690K iAEC2s including TNFa signaling via 
NFkB, inflammatory response, IL6 JAK STAT3 signaling, interferon gamma response, 
TGF beta signaling, unfolded protein response, complement, IL2 STAT5 signaling, 
apoptosis, interferon alpha response (FDR<0.05, Fig 3.7B). In contrast, proliferative and 
metabolic pathways such as E2F targets, G2M checkpoint, mitotic spindle, and glycolysis 




related pathways such as fatty acid metabolism, peroxisome, adipogenesis, although not 
statistically significant, together suggestive of a more proliferative and functional iAEC2 
phenotype more dedicated to surfactant homeostasis. GSEA analysis of W308R mutant 
iAEC2 and its corrected cW308R iAEC2s revealed similar enrichment of inflammatory 
pathways including TNFa signaling via NFkB, inflammatory response, IL6 JAK STAT3 
signaling, IL2 STAT5 signaling, interferon alpha, interferon gamma (Fig 3.7C, 
FDR<0.05) and downregulated in proliferative, metabolic and lipogenic pathways such as 
MYC targets, E2F targets, G2M checkpoints, mTORC1 signaling, oxidative 








 Pairwise comparisons between corresponding mutant and WT ABCA3:GFP+ 
iAEC2s revealed 1096 DEG in the E690K mutant (E690K-AG) and 816 differentially 
expressed genes in the W308R mutant (W308R-AG) compared to the wildtype iAEC2s 
(WT-AG, FDR<0.05, absolute log2FC>1). Analyses of DEGs by GSEA revealed 
enrichment of similar pathways shared with the patient iAEC2 dataset (Fig 3.7 D, E) 
including TGFB signaling, hypoxia, epithelial mesenchymal transition, and IL2_STAT 
pathways (Fig 3.7H). Contrary to patient iAEC2s, we found proliferative gene sets such 
as mitotic spindle, G2M checkpoint, and E2F targets to be enriched in the mutant 
iAEC2s, however, consistent with gene-corrected patient iAEC2s, surfactant-related 
pathways such as adipogenesis, peroxisome, fatty acid metabolism were enriched in the 
WT-AG cells (Fig 3.7D, E). Most notably, however, the TNFa signaling via NFkB 
pathway was consistently shared across all 4 mutant lines in the two distinct genetic 
backgrounds (patient-intrinsic iPSC background and healthy BU3 iPSC donor 
background, Fig 3.7B-D).  
Proliferative Differences Between Mutant and Gene-corrected iAEC2s 
 To assess whether both ABCA3 mutations had negatively impacted iAEC2 
proliferation as predicted by bulk RNA sequencing results (Fig 3.7), we performed EdU 
incorporation assays to formally quantify proliferation in all patient iAEC2 lines. 
Comparing 24-hour EdU incorporation by SFTPCtdTomato+ iAEC2s within each syngeneic 
iAEC2 pairs, we found no proliferative difference between W308R and cW308 iAEC2s 
but lower proliferation in E690K iAEC2s with proliferating cells making up 




iAEC2s (Fig 3.8C). To see whether proliferative differences functionally translated to 
changes in clonogenicity, we performed colony forming efficiency (CFE) assays on day 
57 epithelial sphere outgrowths from day 43 plated SFTPCtdTomato+ patient iAEC2s (Fig 
3.8A). Consistent with no differences the EdU incorporation, we found no CFE changes 
in the W308R compared cW308 iAEC2s, but we observed around a 3-fold higher CFE in 
the cE690 iAEC2s with 6.97%±0.33 compared to the E690K mutant with 2.38%±0.23 





E690K and W308R ABCA3 Mutations Increase iAEC2 NFkB Signaling Resulting in 
Secretion of Inflammatory Cytokines 
 Since transcripts related to NFkB signaling were enriched in ABCA3 mutant 
iAEC2s, we next sought to validate this finding by quantifying the activity of NFkB 
signaling in iAEC2s. To quantitate the level of canonical NFkB pathway activity, we 




carrying a dual gene expression cassette that included a constitutively active GFP reporter 
and a luciferase reporter driven by a minimal promoter with adjacent enhancer consisting 
of the p50/p65 heterodimer consensus binding sequence (Fig 3.8D). Analysis of 
luciferase activity in GFP+ transduced iAEC2s by luminescence measurement revealed 
greater than 2-fold increase in NFkB pathway activity in the E690K mutant and a near 7-
fold increase in the W308R mutant (Fig 3.8E). Next, to see whether increased NFkB 
activity by ABCA3 mutant iAEC2s resulted in the release of NFkB-driven cytokines, 
supernatants from 2D monolayer-cultured mutant or gene-corrected patient iAEC2s were 
harvested for luminex screening assay. Using this methodology, we did not find 
significant differences in the levels of cytokines released by E690K iAEC2s, however, in 
the W308R and cW308 comparison, we did find increased level of proinflammatory 
cytokines: CX3CL1, a potent chemoattractant for lymphocytes and macrophages and a 
known contributor the pathogenesis of other ILDs 155, 156,157, and MMP-10, a recently 
proposed biomarker for idiopathic pulmonary fibrosis158 (Fig 3.8F).  
Discussion 
 Available treatments for patients with ABCA3 mutations are limited, with the 
only effective option being lung transplantation, as was the case for our homozygous 
E690K and W308R ABCA3 mutant patients (Fig 3.1). Lung transplantation is associated 
with high morbidity and mortality. So far, development of therapeutic alternatives has 
been challenged by our inability to access and culture primary diseased AEC2s, the origin 
of disease pathogenesis. In the present study, we overcome these hurdles by developing a 




containing iPSC lines, enabling the analysis of ABCA3 mutant phenotypes. Through 
functional and transcriptomic analyses, we find our iAEC2 model recapitulates clinically 
observed surfactant deficiency and predicts increased NFkB signaling as part of a larger 
inflammatory response originating from ABCA3 mutant iAEC2s with resultant release of 
inflammatory cytokines, providing the foundation for the development of the first 
pathway-specific intervention of ABCA3 mutations and prevention of downstream 
disease pathogenesis. 
 Based on the surfactant secretion capability in PSC-derived iAEC2s detailed in 
Jacob et al. (2017), we sought to assess whether surfactant deficiency would also be 
recapitulated in our ABCA3 mutant iAEC2s, as a proof of concept for our ABCA3 
disease model. Because apically secreted surfactant is difficult to harvest in the a 3D 
spherical culture system, we develop a 2D monolayer culture system for real-time 
visualization of surfactant secretion in iAEC2s, taking advantage of our previously 
developed ABCA3:GFP fusion reporter system, enabling identification of LB exocytosis 
outlined by the fluorescent fusion protein (chapter 1, Fig 3.4). Using this system, we 
enabled quantitative measurements of surfactant lipids in our patient iPSCs-derived 
iAEC2s, which revealed decreased levels of overall PC as well as the surfactant-specific 
phospholipid, DPPC (Fig 3.4). Transcriptionally, in our gene set enrichment analyses of 
bulk RNA sequencing comparing ABCA3 mutant iAEC2s to syngeneic gene-corrected or 
wildtype iAEC2s (Fig 3.7), we also found depletion of lipogenic pathways in ABCA3 
mutant iAEC2s, reflecting decreased surfactant processing capabilities by the mutant 




showing attenuated surfactant phospholipid levels and increased resultant alveolar 
surface tension in patients with ABCA3 mutations 29,67. Using CRISPR/Cas9-based 
footprint free gene correction, we then rescued ABCA3 phospholipid transporting 
function (Fig 3.2, 3.3), thus completing the platform for disease modeling using patient 
iPSC-derived iAEC2s, maintaining the patients' own disease-relevant genetic 
backgrounds.  
 To see whether decreased surfactant secretion resulting from two different 
ABCA3 mutations is associated with mutant ABCA3 protein mistrafficking or 
abnormally small and dense LB morphologies found in patients (Fig 3.1) 21,68,70, we used 
iAEC2s derived from iPSC lines CRISPR/Cas9-mutagenized to express E690K and 
W308R mutant variants of the ABCA3:GFP protein to study mutant ABCA3 trafficking 
and measure LB sizes outlined by these mutant fusion proteins (Fig 3.5). Using these 
tools, we confirmed that similar to a previous study using HEK293 cells 77, the E690K 
mutant protein retained wildtype protein trafficking to LBs. Unexpectedly, we also found 
W308R to traffic similarly to the wildtype protein, contrary to in silico models using 
sequence-based protein conformational algorithms 159-161 predicting the mutation to result 
in a mistrafficking phenotype. However, while both mutant proteins retained wildtype 
trafficking pattern, we noticed LBs outlined by the mutant ABCA3 fusion proteins to be 
significantly smaller compared to the wildtype protein. Combined with measurements of 
decreased surfactant lipids in patient iAEC2s (Fig 3.4), this phenotype further supports 
our current understanding of ABCA3 as the major surfactant lipid transporter in AEC2s 




restore ABCA3 function. Encouragingly, based on similarities between CFTR (ABCC7), 
itself an ABC transporter protein 162 and the causal gene for cystic fibrosis163-165, recent 
studies have attempted to repurpose drugs developed to modulate CFTR function for 
restoration of ABCA3 function in cancer cell line models. These studies have used 
readouts of ABCA3+ vesicle sizes and ABCA3 mistrafficking phenotypes from 
overexpression of mutant ABCA3 proteins in A549 cells 166,167. While significant 
concerns remain regarding the biological relevance of A549 cells, an adenocarcinoma 
cell line thought to be derived from AEC2s, our own head to head comparison between 
A549 ABCA3:GFP overexpression model and our iAEC2s expressing endogenous levels 
of ABCA3:GFP fusion proteins (Fig 3.6) demonstrated the same protein trafficking 
patterns showing smaller LBs formed by E690K and W308R mutants. Thus, our data 
lend support for the use of A549 cells for the purpose of high throughput drug screening 
to be confirmed in a more physiologically relevant cell model.  
 Our ABCA3 disease model using footprint free CRISPR/Cas9 gene editing tools 
enabled pairwise comparison of syngeneic iAEC2s across different genetic backgrounds: 
patient's own genetic background containing any genetic susceptibility to the disease, as 
well as mutagenized wildtype iPSC lines (BU3) engineered to have the same ABCA3 
mutations, allowing for stringent identification of mutant-specific pathways in both a 
diseased and healthy genetic background. Transcriptomic analyses by bulk RNA 
sequencing across all three genetic backgrounds (E690K patient, W308R patient, knock-
in mutant BU3 iPSC lines) revealed enrichment of a wide range of inflammatory 




(Fig 3.7). In addition to the NFkB signaling pathway, we found upregulation of the TGFß 
signaling pathway in 3 out of the 4 ABCA3 mutant iAEC2 lines (E690K, E690K-AG, 
W308R-AG, FDR<0.05, Fig 3.7). TGFß signaling is a well-described pathway 
upregulated in mouse lung fibrosis models 168-170 and in patients with idiopathic 
pulmonary fibrosis 171-173, contributing to the pathogenesis of pulmonary fibrosis by 
stimulating ECM deposition by pulmonary fibroblasts 174. Closer examination of enriched 
genes in the E690K mutant patient iAEC2s revealed TGFB1, the gene encoding for the 
TGF-ß1 ligand, to be the number 8 differentially expressed gene. Thus, it is conceivable 
that as a result of ABCA3 mutations, TGF-ß1 ligands secreted by diseased iAEC2s might 
stimulate increased ECM deposition, leading to lung remodeling and fibrosis seen in our 
two patients explant histology (Fig 3.1) as well as in chILD caused by other ABCA3 
mutations. Consequentially, upregulation of these inflammatory pathways implies a 
toxic-gain of function phenotype resulting from ABCA3 mutations instigated by the 
AEC2s, challenging the previous paradigm that ABCA3 mutations only constitute loss of 
function mutations 21,55. Our observations are also consistent with published in vivo 
mouse conditional Abca3 knock-out model which showed increased lung inflammatory 
phenotypes followed by surfactant deficiency 175. 
 Interestingly, in patient iAEC2s, proliferative pathways were enriched in the 
gene-corrected iAEC2s (Fig 3.7 B, C) with the cE690 gene-corrected iAEC2s 
demonstrating improved proliferation and colony forming efficiency (Fig 3.8 A-C). The 
proliferative advantage of AEC2s containing functional ABCA3 may lend support for the 




option using methods showcased recently in mice treated with in utero gene-correction of 
the I73T SFTPC mutation 176 by Alapati et al. (2019). We did not see functional 
proliferative differences in the W308R iAEC2s, potentially highlighting ABCA3 
mutation-specific effects on AEC2 physiology. We also did not observe enrichment of 
proliferative pathways in the CRISPR/Cas9 mutagenized lines. However, these lines do 
not contain disease-relevant genetic backgrounds that potentially contribute to lung 
disease susceptibility, signifying the importance of having disease-relevant, genetically-
controlled lines for disease modeling in order to identify patient-specific phenotypes.  
 As indicated in our transcriptomic and later validated using lentiviral reporter 
assays (Fig 3.7), NFkB signaling appeared to be a shared mechanism activated in 
response to each of the two ABCA3 mutations in our study. An important question to 
consider is how NFkB signaling is activated in iAEC2s. It is possible that some of the 
enriched pathways upregulated in mutant iAEC2s are upstream of NFkB signaling such 
as the unfolded protein response (UPR) or dysregulation of overall intracellular lipid 
homeostasis without adequate ABCA3 function. Future studies focused on validation of 
these potential upstream pathways will likely further inform disease mechanisms.  
 As a result of increased, NFkB pathway activity, we found secretion of 
proinflammatory cytokines MMP10 and CX3CL1 in the W308R mutant iAEC2s (Fig 7). 
However, we found no cytokines differentially secreted in our E690K, cE690 syngeneic 
iAEC2 pairs, perhaps reflective of the smaller relative induction of in NFkB pathway 
activity in E690K iAEC2s indicated by the NFkB luciferase reporter assay (Fig 3.8). 




interface cultures or co-culture with relevant immune and mesenchymal cell types, may 
facilitate a more comprehensive study on the paracrine effects of diseased AEC2s as a 
result of NFkB upregulation caused by ABCA3 mutations.  
 Thus, our study reports the first ABCA3 disease model using primary-like human 
AEC2s demonstrating the epithelial-intrinsic contribution to chILD pathogenesis. This 
model should now facilitate the development of effective targeted therapies for chILD 
patients with ABCA3 mutations. 
 
Preliminary data and future directions  
Drug treatment to restore iAEC2-intrinsic effects of ABCA3 mutations  
Rationale:  
 
 Pharmacological treatment of ABCA3 mutant patients have traditionally relied on 
corticosteroids, artificial surfactant, prophylactic antibiotics like azithromycin and 
immunomodulatory agents like hydroxychloroquine, based on indirect evidence, case 
reports, and clinical observations, resulting in varied clinical outcomes. Recently, using 
the A549 overexpression model to study mutant ABCA3 phenotypes, one study has 
demonstrated restoration of normal ABCA3 intracellular trafficking from a mistrafficking 
phenotype by repurposing small molecules (C13 and C17) previously developed to 
modulate CFTR function in cystic fibrosis (CF) 166. Another study has demonstrated 
some potentiation of mutant ABCA3 lipid transport function by other CFTR drugs 
ivacaftor and genistein by measuring ABCA3+ vesicle sizes 167, raising the possibility 




member of the ABC family of transporters, can also be used for ABCA3. However, key 
limitations of these studies lie in their reliance on A549 cells, a cancer cell line that does 
not naturally produce surfactant nor recapitulate AEC2 physiology, undermining the 
biological relevance of these findings.  
Preliminary Results:  
 To see whether treatment with small molecules can restore mutant ABCA3 
function, measurable by the readout of LB size, we plated day 152 E690K and day 258 
W308R mutant ABCA3:GFP expressing iAEC2s on 2D monolayered culture in chamber 
slide wells and treated each well for 72 hours with either: 1) DMSO vehicle control or 2) 
combined cocktail of ivacaftor (3.33µM), lumacaftor (3.33µM), and tezacaftor(3.33µM) 
CFTR modulators, 3) C13 (5µM) and C17 (5µM) molecules, and 4) hydroxychloroquine 
(10µM, Fig 3.9A). Comparison with untreated control cells showed no improvement in 
ABCA3+ vesicle sizes in the W308R mutant (data not shown), but we observed an 
increase in vesicle sizes in E690K mutant iAEC2s with C13+C17, and CFTR modulators, 
and a large increase in hydroxychloroquine treated cells (Fig 3.9 B, C), potentially 
indicative of improved ABCA3 function. To functionally characterize whether changes in 
LB sizes translate to improved surfactant lipid secretion or reduced inflammatory 
signaling in these iAEC2s, future repeat experiments will focus on lipidomic analyses (as 
in Fig 3.3) and lentiviral reporter assay for NFkB pathway activity (as in Fig 3.8) of drug 
treated cells compared with their syngeneic iAEC2s expressing wildtype ABCA3, These 
studies will enable quantitative evaluation of the clinical use of hydroxychloroquine and 









 Protein-protein interactions with ABCA3 are largely unknown. Improved 
characterization of ABCA3 binding partners as well as its larger protein regulatory network 
will likely inform our understanding on its normal function and how such function can be 





 Day 40-187 cell pellets across 3 different distal lung differentiations of BU3-AG 
iAEC2 cultures expressing wildtype ABCA3:GFP fusion proteins were lysed in buffer 
containing 30 mM Tris-HCl, 150 mM NaCl, 1% N-dodecylmaltoside, and complete 
protease and phosphatase inhibitors (Roche) followed by 1 freeze thaw cycle and 
sonication at 10%, 15s, 3s pulse. Supernatants were collected after centrifugation at 
14,000g for 30 min at 4°C. Immunoprecipitation was performed with anti-GFP 
(Invitrogen GF28R) or IgG control and Protein G Dynabeads (Invitrogen), 3 hour 
incubation at 4°C. Protein complex bound beads were washed twice using Lysis buffer 
without detergent and once with 100 mM triethylammonium bicarbonate. On bead 
Trypsin digestion was performed with 750ng of trypsin (Pierce) in 100 mM 
triethylammonium bicarbonate overnight at 37°C. Peptides were desalted using a C18 
ZipTip (Millipore) and subjected to reverse-phase LC separation on a 60-min gradient 
and analyzed on a Q Exactive HF-X (Thermo Fisher Scientific). Data-dependent 
fragmentation used collision-induced dissociation. RAW files were searched using 
MaxQuant under standard settings using the UniProt human database, allowing for two 
missed trypsin cleavage sites, variable modifications for N-terminal acetylation, and 
methionine oxidation. Candidate peptides and protein identifications were filtered on the 
basis of a 1% false discovery rate threshold based on searching of the reverse sequence 








 Because primary AEC2 cells are difficult to culture in vitro and other cell line 
models do not recapitulate AEC2 biology, our ABCA3:GFP fusion constructs combined 
with our primary cell-like iAEC2 model provide the ideal platform to identify 
biologically relevant ABCA3 interacting partners. To identify proteins normally 
associated with ABCA3, we harvested cell pellets of iAEC2s expressing wildtype 
ABCA3:GFP and performed co-immunoprecipitation, using an antibody against GFP to 
pulldown ABCA3:GFP and its interacting proteins, followed by mass spectrometry 
analysis. We found GFP pulldown enriched for ABCA3 protein itself, consistent with a 
previous report by Frixel et al., (2016) showing homooligomerization of ABCA3 in 
HEK293 cells transfected with ABCA3 expressing vectors 177. In theme with ABCA3's 
surfactant transporting function, we also found other proteins with known functionality in 
phospholipid transport including ATP11A, a plasma membrane ATP dependent 
phosphatidylcholine flippase  178,179; RAB7A, a GTPase known to regulate lysosome-
derived organelle transport, such as LB 180; TMED10, a vesicular transport protein181, 
potentially contributing to ABCA3 recycling from the plasma membrane after LB 
exocytosis. Future studies will focus on using immunofluorescence techniques to validate 
these potential binding partners and identify possible disruption in normal ABCA3 






 Our studies have made significant inroads, elucidating the heterogeneous nature 
in vitro distal lung differentiation (chapter 1), and generating an AEC2 disease model that 
not only captures patient disease phenotypes but also contributed to broader 
understanding of chILD pathogenesis caused by ABCA3 mutations (chapter 2). Here we 
highlight key findings, remaining questions, and implications for the future of AEC2 
research and disease modeling. 
ABCA3:GFP fusion reporter system and the use of surrogate surface markers for in 
vitro isolation of iAEC2s 
 In the absence of viable primary cell culture models, the use of PSCs combined 
with fluorescent reporters such as the NKX2-1GFP 109specific to the lung epithelial lineage 
and SFTPCtdTomato 97and SFTPCGFP 99reporters for in vitro-derived AEC2s have been 
instrumental not only as a readout to identify relevant biological pathways required to 
derive these cell types, but has also enabled isolation of these same cells for downstream 
experiments previously inaccessible to most researchers. Building on these previous 
advances delineating methods to derive iAEC2s, in this dissertation, we generated the 
first AEC2-specific fusion reporter system by targeting the endogenous ABCA3 locus, an 
essential gene for AEC2 surfactant metabolism and LB biogenesis. We demonstrated that 
the localization pattern of ABCA3 protein to the limiting membrane of LBs in our in 
vitro iAEC2 model simultaneously enabled live-cell visualization of LB morphology, 
intracellular localization, and of surfactant exocytosis, opening doors to the use of AEC2-




biology such as surfactant metabolism. Importantly, the use of ABCA3:GFP fusion 
reporters will be a more biologically relevant alternative to study LBs compared to 
current uses of lysotracker dyes78,113 or staining against LAMP1 or LAMP3 78, markers 
that non-specifically label non-LB lysosomal organelles in addition to LBs. 
 An added utility of these reporters is that they have facilitated discovery of 
surrogate surface markers 109,113,135. Consistent with previous reporting by Korogi et al. 
(2019) demonstrating enrichment of cells expressing the AEC2 program using cell 
sorting against SLC34A2, a sodium phosphate transporter, we also found SLC34A2 to 
enrich for ABCA3:GFP+ iAEC2s in our iAEC2 model, validating SLC34A2 as a useful 
surrogate surface marker to enrich iAEC2s across multiple genetic backgrounds, enabling 
isolation of pure populations of iAEC2s derived from PSC lines without the need for 
time-intensive gene targeting of knock-in reporters.  
Heterogeneity and plasticity of in vitro distal lung differentiation 
 In our study highlighting the heterogeneity of in vitro differentiated iAEC2s 
(chapter 1), we find populations of cells previously expressing markers and 
transcriptomic signatures of iAEC2s de-differentiating into a more progenitor-like cell 
type reminiscent of the distal bud-tip cells in the developmental lung. Even among the 
iAEC2 population, differing populations appear, first visualized using our bi-fluorescent 
(SFTPCtdTomato, ABCA3:GFP) reporters and transcriptomically and functionally defined 
by differences in proliferation and surfactant metabolism. While cell sorting using AEC2 
or lung-specific fluorescent reporters followed by extended passaging 124 can improve the 




maintaining high levels of cellular homogeneity defined by stable and continuous 
expression of SFTPCtdTomato or ABCA3:GFP reporters across many passages. Possible 
explanations to ponder may include aberrant or the absence of appropriate epigenetic 
changes, rendering these cells to retain a certain degree of cellular plasticity. Future 
experiments defining the epigenetic changes of in vivo lung differentiation in comparison 
to changes occurring in in vitro derived iAEC2s will likely inform a more stable and 
reproducible differentiation of iAEC2s. Additionally, the lack of physiological stimuli 
such as stretching, as normally occurs in a gas exchanging alveolus, and the absence of 
other non-epithelial cell types, such as the mesenchymal, endothelial or immune cell 
types may also contribute to the loss of AEC2 program and the transcriptomic differences 
compared to primary AEC2s 97. Future experiments focused on culturing PSC-derived 
iAEC2s in a more physiologically relevant condition such as in air liquid interface (ALI) 
or in co-culture with other cell types will certainly shed new insights into how these non-
epithelial cells types affect iAEC2 physiology such as surfactant metabolism and 
transdifferentiation into AEC1s.  
Next steps in ABCA3 disease modeling  
 The ultimate goals of disease modeling are not only to recapitulate disease 
phenotypes but also to gain new knowledge on disease pathogenesis. iPSCs derived from 
the patient's own cells provide unique opportunities to capture the disease-relevant 
mutation and genetic background as well as a documentation of personalized clinical 
histories as roadmaps to developing accurate disease models. Using such roadmaps, in 




patients' disease phenotypes of surfactant deficiency. Moreover, using a different genetic 
background (BU3) combined with the patients' own genetic backgrounds, we identified a 
number of inflammatory pathways including TGFß signaling and NFkB signaling to be 
upregulated irrespective of genetic backgrounds, paving the way for future trials on 
pharmacological intervention targeted at these pathways.  
 Recently, our lab has published an example of successful recapitulation surfactant 
protein B deficiency caused by SFTPB121ins2 mutation97. Other have also modeled another 
AEC2 disease such as the Hermansky-Pudlak syndrome 113,114 using in vitro-derived 
AEC2-like models. With the faithful recapitulation of disease phenotypes, next steps of 
AEC2 disease modeling will focus on functional restoration of affected mutations with 
many possibilities including gene-, cell-, or drug-based therapies. Unique disease 
pathways, as identified in our study for the two ABCA3 mutations, will likely inform and 
guide future development of mutation-specific drugs targeted at the NFkB pathway. 
Moreover, accurate disease models will also likely inform efficacy of existing 
pharmacological treatments, such as hydroxychloroquine, azithromycin, or potentially 
repurposed CFTR modulators, enabling objective readouts on restoration of AEC2 
function such as surfactant production or secretion of pro-inflammatory cytokine 
secretions.  
 Advances in gene-editing technologies have broaden possibilities on effective 
methods of gene therapy of monogenic lung diseases showcased in a recent study 
describing successful in utero correction of SFTPCI73T mutation in mice by CRISPR-




to use similar methods to deliver CRISPR-oligos to correct certain ABCA3 mutations, 
such as those resulting in aberrant intronic splice sites, in utero, without the need for 
homologous recombination. Gene therapy for other ABCA3 mutations requiring more 
than simple ablation of intronic sequences, but requiring homologous gene 
recombination, it is possible that with while gene-correction may occur in low 
efficiencies, the small population of gene-corrected AEC2s with restored ABCA3 
function may have a proliferative advantage as shown by us for the E690K mutant and in 
conditional ABCA3-KO mice model175, overtime replacing damaged AEC2s. 
 Lastly, recent studies demonstrating recellularization of decellularized rat lung 
182as well as advances in mouse lung engraftment studies shed considerable excitement 
over the possibility of one day taking advantages of iPSCs as an inexhaustible source of 
patient-specific cells to re-introduce gene-corrected and differentiated iAEC2s back to the 
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